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ABSTRACT 
 
 
 Pattern recognition receptors are innate immune sensors that recognize pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs) with crucial roles in host defense against microbial infection, autoimmune 
diseases and cancer. Cytosolic nucleic acids including DNA and RNA originate from 
pathogens or self-cells, which form major groups of PAMPs and DAMPs. A range of 
nucleic acid sensors have evolved to sense various types of nucleic acids. How different 
DNA-sensing pathways regulate microbial infection and cancer is the focus of this 
dissertation. 
 
Stimulator of IFN genes (STING) is a cytosolic innate immune sensor for cyclic 
dinucleotides that also serves a dual role as an adaptor molecule for a number of 
intracellular DNA receptors. A physiological role for STING in cancer was previously 
unknown. We showed that STING-deficient mice were highly susceptible to colitis-
associated colorectal cancer. Colons of STING-deficient mice exhibited significant 
intestinal damage and overt proliferation with increased levels of pro-inflammatory 
cytokines during early stages of tumorigenesis, uncovering an unexpected and important 
role for STING in mediating protection against colorectal tumorigenesis. 
 
Absent in melanoma 2 (AIM2) forms an inflammasome with ASC and caspase-1 
upon recognition of double-stranded DNA (dsDNA) in the cytosol leading to caspase-1 
activation and caspase-1-dependent pyroptosis and release of cytokines IL-1 and IL-18. 
Mutations in AIM2 are frequently identified in patients with colorectal cancer, but how 
AIM2 modulates colonic tumorigenesis is unknown. We found that AIM2-deficient mice 
were hypersusceptible to colonic tumor development. While production of 
inflammasome-associated cytokines and other inflammatory mediators was largely intact 
in AIM2-deficient mice, intestinal stem cells lacking AIM2 were prone to uncontrolled 
proliferation. Aberrant Wnt signaling expanded a population of tumor-initiating stem 
cells in the absence of AIM2 driving the tumor development in AIM2-deficient mice. In 
addition to its role in cancer, AIM2 recognizes bacteria including Francisella tularensis 
subspecies novicida (F. novicida) and induces inflammasome responses. Type I 
interferon (IFN) signaling drives activation of AIM2 inflammasome in F. novicida-
infected macrophages; however, the relative contribution of IFNs and inflammasome 
responses in host defense against F. novicida infection is less understood. We found 
intact AIM2 inflammasome responses in mice lacking type I IFN signaling during 
infection with F. novicida. Lack of type I IFN signaling conferred protection to F. 
novicida infection in contrast to the increased susceptibility in AIM2-deficient mice. 
Interestingly, mice lacking both AIM2 and IFNAR2 were protected against the infection 
indicating a dominant role for type I IFNs in mediating detrimental responses despite the 
protective AIM2 inflammasome responses. Gasdermin D (GSDMD) is activated by 
caspase-1 to generate pores on the plasma membrane to induce pyroptosis downstream of 
the AIM2 inflammasome. We also demonstrated that mice lacking GSDMD were highly 
susceptible to F. novicida infection. Interestingly, GSDMD is required for optimal 
 v 
caspase-1 activation during F. novicida infection, providing protection to the host during 
the infection.  
 
 In addition, we identified differential mechanisms regulating expression of 
inflammasome-associated cytokines IL-1 and IL-18. IL-1 is only induced in response 
to inflammatory stimuli and its expression is not sustained during chronic treatment, 
while IL-18 is constitutively expressed and further induced after the stimulation in a type 
I IFN signaling-dependent manner.  
 
Overall, this dissertation addresses protective roles for cytosolic nucleic acid-
sensing molecules, STING and AIM2, in colon cancer, uncovers an interplay between the 
AIM2 inflammasome and type IFN signaling during F. novicida infection, and 
demonstrates a novel function for GSDMD in regulating AIM2 inflammasome. The 
dissertation finally describes distinctive mechanisms governing inflammasome-associated 
cytokines IL-1 and IL-18.  
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CHAPTER 1.    INTRODUCTION 
 
 
Background 
 
 
Cytosolic Nucleic Acids Sensing by Innate Immune Receptors 
 
Pattern recognition receptors are germ-line encoded, innate immune sensors that 
recognize conserved molecules derived from microbes or disturbance of homeostatic self-
cells, namely PAMPs or DAMPs. Cytosolic nucleic acids such as DNA and RNA form a 
major group of PAMPs and DAMPs, which can be utilized by microbes including 
viruses, bacteria and fungi as genetic materials and are sensed by cytosolic nucleic acids 
sensors upon being released into cytoplasm during the life cycle of the microbes. Under 
certain conditions, nucleic acids of self-origin gain access to the cytoplasm and are 
recognized by cytosolic sensors leading to autoimmunity [1]. 
 
RNA sensors retinoic acid inducible gene I (RIG-I) and melanoma differentiation-
associated protein 5 (MDA5) recognize short and long RNA fragments respectively [2]. 
RIG-I also detects 5’-tri-phosphate and di-phosphate RNA [3-5]. A common adaptor, 
mitochondrial antiviral-signaling protein (MAVS) is activated downstream of RIG-I or 
MDA5 to induce production of type I IFNs and other inflammatory cytokines [6-9]. RIG-
I and MDA5 are critical in mediating immune responses to a variety of RNA viruses, 
such as influenza virus, hepatitis C virus and myocarditis virus [10, 11]. On the other 
hand, cytosolic DNA is sensed mainly by cyclic GMP-AMP synthase (cGAS)- STING 
pathway and AIM2, which will be discussed in details below. 
 
 
Recognition of Cytosolic DNA by cGAS-STING Pathway and Their Potential Role 
in Colon Cancer 
 
DNA sensor, cGAS, recognizes dsDNA in the cytoplasm and mediates synthesis 
of 2’3’-cyclic GMP-AMP (cGAMP), which binds and activates downstream adaptor 
STING (Figure 1-1) [12-16]. Bacteria-derived cyclic-di-AMP (c-di-AMP) and cyclic-di-
GMP (c-di-GMP) in the cytoplasm can also bind and activate STING, placing STING as 
a direct sensor for cytosolic cyclic dinucleotides [17]. Activated STING recruits TANK-
binding kinase 1 (TBK1) to induce phosphorylation of interferon-regulatory factor (IRF) 
3 and IRF3-mediated expression of type I IFNs and other cytokines [18-20]. The adaptor 
STING has been shown to mount host defense against infection by DNA and RNA 
viruses and bacteria such as Francisella, Listeria and Mycobacterium genera [21]. The 
RNA-sensing pathway has been implicated to play a role in cancer biology in addition to 
its critical function in host defense against viral and bacterial infection. Treatment of 
DNA demethylation agents to colon tumor cells induces viral mimicry, leading to MDA5 
and MAVS-dependent production of IFNs with anti-tumor abilities [23]. However, the 
role of the STING-mediated DNA-sensing pathway in cancer, particularly colon cancer, 
is rather understudied. Colon cancer is the 3rd most commonly diagnosed cancer and 4th   
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Figure 1-1. Diagram of cGAS-STING pathway. 
cGAS senses and binds to cytosolic dsDNA leading to production of cGAMP. cGAMP 
then binds and activates the downstream adaptor STING to induce recruitment of TBK1 
and phosphorylation of IRF3. Phosphorylated IRF3 forms dimers to enter the nucleus to 
mediate transcription of type I IFNs and other inflammatory cytokines. Bacteria such as 
L. monocytogenes release c-di-AMP and c-di-GMP into the cytosol and activate STING 
directly [17, 22].  
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leading cause for cancer-related deaths worldwide [24]. The incidence and mortality of 
colon cancer are rapidly increasing in developing countries [25]. Inflammation functions 
as a driving force to promote colon tumorigenesis. Clinical data support this notion by 
observing increased probability for patients with ulcerative colitis to develop colon 
cancer [26]. Moreover, previous studies have suggested that innate immune sensors can 
modulate the magnitude of colon inflammation thereby regulating development of colon 
cancer [27-31], underscoring a potential role for the DNA-sensing pathway governed by 
cGAS and STING in colitis-associated cancer. 
 
 
AIM2 in Colon Cancer and Francisella Infection 
 
dsDNA in the cytoplasm can also be recognized by AIM2 (Figure 1-2) [32-35]. 
AIM2 binds to DNA via a HIN200 domain which allows its PYRIN domain to interact 
with the PYRIN domain of the bipartite adaptor molecule ASC [36]. The CARD domain 
of ASC recruits and interacts with the CARD domain of caspase-1 to form a multi-
protein complex named the inflammasome [36]. The AIM2 inflammasome mediates 
activation of caspase-1 leading to caspase-1-depdendent maturation and secretion of IL-
1 and IL-18 and induction of pyroptosis. The AIM2 gene was initially isolated by 
investigating tumorigenicity of melanoma cells [37]. Later studies identified mutations 
and reduced expression of AIM2 gene in human colon tumors and colon tumor cell lines 
[38-40]. Moreover, a poorer survival rate has been reported in colon cancer patients 
bearing lower AIM2 expression in the tumors [40]. Besides its potential role in colon 
cancer, AIM2 has been established as a critical sensor for microbial infection. AIM2 is 
responsible for inducing inflammasome responses upon infection by viruses including 
mouse cytomegalovirus (MCMV) and vaccinia virus, bacteria including Francisella 
tularensis Live Vaccine Strain, F. novicida, Listeria monocytogenes (L. monocytogenes) 
and Mycobacterium, and fungi including Aspergillus fumigatus [1]. Of these, F. novicida 
is a gram-negative bacterium that exclusively activates AIM2 inflammasome in a type I 
IFN signaling-dependent manner in murine macrophages and dendritic cells (Figure 1-2) 
[41-43]. After being engulfed in macrophages, F. novicida escapes the Francisella-
containing vacuole and replicates in the cytoplasm. During this process, the cGAS-
STING pathway senses F. novicida leading to production of type I IFNs [44-46]. Type I 
IFNs induces expression of transcriptional factor IRF1 and further IRF1-dependent 
expression of immunity-related GTPase family member B10 (IRGB10) and guanylate-
binding proteins (GBPs) including GBP2 and GBP5 [44, 45, 47]. IRGB10 and GBPs 
belong to a family of IFN-inducible GTPases and are proteins of cell-autonomous 
immunity [48]. During F. novicida infection, they are targeted to the cell membrane of 
bacteria leading to bacterial killing and release of bacterial ligands including DNA into 
the cytoplasm, thereby activating AIM2 inflammasome [44, 45, 47]. 
 
While AIM2 is required for host protection against F. novicida infection, the role 
of type I IFN signaling during bacterial infection in vivo is diverse, which can be either 
beneficial or detrimental depending on the pathogen. Type I IFNs provide protection to 
the mice infected with Escherichia coli (E. coli), Streptococcus pneumoniae, or 
Streptococcus pyogenes but are deleterious following infection by F. novicida,   
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Figure 1-2. Diagram of AIM2 inflammasome in response to F. novicida. 
Cytosolic F. novicida is recognized by the cGAS-STING pathway leading to production 
of type I IFNs via transcription factors IRF3 and IRF7. Type I IFNs bind to the 
heterodimeric receptor consisting of IFNAR1 and IFNAR2 to induce formation of a 
signaling transducer named interferon-stimulated gene factor 3 (ISGF3), which include 
signal transducer and activator of transcription (STAT) members STAT1, STAT2 and 
IRF9 to mediate expression of IRF1 and in turn IRF1-dependent expression of IRGB10 
and GBPs. These IFN-inducible GTPases are recruited to the bacteria membrane to 
induce bacteriolysis and release of bacterial DNA into the cytosol to activate the AIM2 
inflammasome. TheAIM2 inflammasome activates caspase-1. Activated caspase-1 
cleaves GSDMD to release the N-terminal portion to induce pyroptosis by generating 
pore structures on the cell plasma membrane. Caspase-1 also cleaves pro-IL-1 and pro-
IL-18 into their mature form. IL-1 and IL-18 are released from the cell through the 
pores formed by GSDMD. 
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Salmonella enterica, or L. monocytogenes [49, 50]. How the interplay between the 
opposing effects of both type I IFN signaling and the AIM2 inflammasome determines 
the final outcome during host defense against F. novicida infection has remained unclear. 
 
In addition, recent studies have discovered GSDMD as the molecular basis 
underlying pyroptosis downstream of inflammasome activation [51-53] (Figure 1-2). 
GSDMD belongs to gasdermin family of proteins. Inflammatory caspases including 
caspase-11 or caspase-1 cleave a linker region between the N- and C-terminal domain of 
GSDMD, releasing the functional N-terminal fragment from inhibition by the C-terminal 
end [51-53]. The N-terminal portion of GSDMD has been shown to be associated with 
lipid membranes with an ability to directly bind to cardiolipin and phosphoinositides, the 
latter of which are usually located in the inner leaflet of the plasma membrane [54-58]. 
GSDMD forms pores on the membrane and induces cell lysis. In addition, GSDMD-
formed pores allow release of IL-1 and IL-18 independently of pyroptosis [59, 60]. 
While IL-1 and IL-18 have been shown to protect against Francisella tularensis Live 
Vaccine Strain infection downstream of AIM2 inflammasome activation [61, 62], the role 
of AIM2-mediated pyroptosis during Francisella infection has not been studied yet.  
 
 
Regulation of Inflammasome-Associated Cytokines IL-1 and IL-18 
 
IL-1 and IL-18 are members of the IL-1 cytokine family and are synthesized as 
precursor proteins. Upon the assembly of inflammasome, active caspase-1 cleaves IL-1 
and IL-18 leading to their subsequent release from the cell [63]. Interestingly, although 
IL-1 is not expressed under steady state, a cellular pool of IL-18 already exists before 
any inflammatory stimuli, and is ready to be activated and released by the inflammasome 
[64]. Expression of IL-1 is induced when cells are stimulated with different toll-like 
receptor (TLR) ligands or cytokines [65-67]. Several reports suggest that IL-18 
expression can also be induced by several TLR ligands or sendai virus [68-71]. Thus, 
how the levels of IL-1 and IL-18 are differentially regulated by inflammatory signals is 
unclear. 
 
 
Summary and Aims of Dissertation 
 
Upon recognition of dsDNA in the cytoplasm, STING mediates expression of 
type I IFNs and other inflammatory genes, while AIM2 forms an inflammasome to 
induce IL-1 and IL-18 release and pyroptosis. Both DNA-sensing pathways are critical 
in infection and autoimmune diseases, while their roles in cancer are yet to be studied. 
First two aims of this dissertation is to investigate potential functions of STING and 
AIM2 in colon cancer. We hypothesize that they have critical roles during colon cancer 
development. 
 
Upon F. novicida infection in vitro, AIM2 senses bacterial DNA derived from F. 
novicida to form the inflammasome, a process that is dependent on type I IFN signaling. 
However, while the AIM2 inflammasome is protective against F. novicida infection, type 
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I IFN signaling is detrimental to the host during the infection in vivo. The third aim of the 
dissertation is to address the interplay between AIM2 inflammasome responses and type I 
IFN signaling during F. novicida infection in vivo.  Thus, we hypothesize that the 
detrimental type I IFN signaling could interference with the protective AIM2 
inflammasome responses.  
 
The AIM2 inflammasome activates caspase-1 to induce GSDMD-mediated 
pyroptosis and release of IL-1 and IL-18. Fourth aim of the dissertation is to study the 
role of GSDMD downstream of the AIM2 inflammasome during F. novicida infection. 
We hypothesize that GSDMD functions to provide protection to the host during F. 
novicida infection. 
 
 The fifth aim of the dissertation is to characterize mechanisms governing 
expression of IL-1 and IL-18 in response to different inflammatory stimuli. 
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CHAPTER 2.    MATERIALS AND METHODS* 
 
 
Mice 
 
Wide-type (WT) C57BL/6J mice and Irf8tm1.2Hm/J mice (also known as Irf8−/−; 
Stock Number 018298) were purchased from The Jackson Laboratory. STING-deficient 
(Stinggt/gt) mice [72], Aim2−/− mice [43], Asc−/− mice [73], Casp1−/−Casp11−/− mice [74], 
Casp3−/− mice [75], Casp7−/− mice [76], Prom1C-L/+;Ctnnb1lox(ex3)/+ mice [77], Ifnar1−/− 
mice [78], Ifnar2−/− mice [79], Irf3−/− mice [80], Irf4fl/fl-Lysm-Cre mice [81], Irf5−/− mice 
[81], Irf7−/− mice [82], Irf3−/−Irf7−/− mice [83], Irf5−/− mice [83], Irf9−/− mice [84], Ifnar2–
/–Aim2–/– mice [83] and Gsdmd−/− mice [85] have been described previously. Stat1−/− mice 
were provided by Dr. Abhay Satoskar (Ohio State University). Male and female mice of 
6-8 weeks old were used in this study. All mice were bred at the Animal Resource Center 
at St. Jude. Animal studies were conducted according to protocols approved by the St. 
Jude Animal Care and Use Committee. 
 
 
Bacterial Culture and Animal Infection 
 
F. novicida strain U112 was grown overnight at 37 °C in BBL Trypticase Soy 
Broth (TSB) (BD) contaning 0.2% L-cysteine and were 1:10 subcultured for 4 hours. 
Mice were infected subcutaneously with F. novicida in 200 μl PBS. For CFU analysis, 
homogenized liver and spleen tissue samples were plated onto TSB agar containing 0.2% 
                                                 
* Adapted with permission. Zhu Q., Man S.M., Gurung P., Liu Z., Vogel P., Lamkanfi 
M., Kanneganti T.D. (2014). Cutting Edge: STING mediates protection against colorectal 
tumorigenesis by governing the magnitude of intestinal inflammation. Journal of 
Immunology. 193(10):4779-82. Copyright 2014. The American Association of 
Immunologists, Inc. 
 
Adapted with open access permission. Man S.M.*, Zhu Q.*, Zhu L.*, Liu Z.*, Karki R., 
Malik A., Sharma D., Li L., Malireddi R.K., Gurung P., Neale G., Olsen S.R., Carter 
R.A., McGoldrick D.J., Wu G., Finkelstein D., Vogel P., Gilbertson R.J., Kanneganti 
T.D. (2015). Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. 
Cell. 162(1):45-58. (* Co-first author)  
 
Adapted with permission. Zhu, Q. and T.D. Kanneganti, Cutting Edge: Distinct 
Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β. J 
Immunol, 2017. 198(11): p. 4210-4215. Copyright 2017. The American Association of 
Immunologists, Inc. 
 
Adapted with open access permission. Zhu, Q., Man S.M., Karki R., Malireddi R.K., 
Kanneganti, T.D. (2018). Detrimental type I Interferon signaling dominates protective 
AIM2 Inflammasome responses during Francisella novicida Infection. Cell Reports. 22, 
3168-3174. 
 8 
L-cysteine and incubated overnight. For survival analysis following TNF-related 
apoptosis-inducing ligand (TRAIL) neutralization, mice were injected intraperitoneally 
with 300 mg anti-TRAIL monoclonal antibody (N2B2) or immunoglobulin G2a (IgG2a) 
(RTK2758) isotype control (BioLegend) on days 0, 1, and 2 post-infection. For the 
recombinant TRAIL (rTRAIL) experiment, mice were injected intraperitoneally with 10 
mg rTRAIL (PeproTech) or PBS on the same day as infection. 
 
 
Induction of Tumors 
 
For azoxymethane (AOM) and dextran sulfate sodium (DSS) model (Figure 2-1) 
[86], mice were injected intraperitoneally with 10 mg of AOM (Sigma) per kg body 
weight. 5 days later, 3% DSS (molecular mass 36–40 kDa; MP Biologicals) was given in 
the drinking water for 6 days, which was further followed by drinking water for 2 weeks. 
This cycle was repeated twice with 2.5% DSS. Mice were sacrificed on day 80. For Day 
8 samples, mice were injected with AOM, fed 3% DSS for 3 days and sacrificed. For Day 
14 samples, mice were injected with AOM, fed 3% DSS for 6 days and sacrificed 3 days 
later. For co-housing experiments, equal numbers of female WT and female Aim2−/− mice 
were housed in the same cage for 4 weeks. Mice were then housed separately before 
AOM injection and remained separated over the course of the experiment. To induce 
oncogenic Wnt signaling, tamoxifen induction was performed on 2-month-old mice by 
oral gavage with 200 ml tamoxifen (20 mg/ml) in corn oil for 2 days. 
 
 
LDH Release Assay 
 
Cell culture supernatants were collected at the indicated times, and LDH activity 
was measured using the Promega cytotoxicity kit according to manufacturer’s protocols.  
 
 
Microarray Analysis 
 
Mouse Gene 2.0 (Affymetrix) was used to examine the gene expression profiles 
using RNA that was extracted from colon tissues. GSEA software (Broad Institute) was 
used to analyze the relevant signaling pathways. 
 
 
Bone Marrow Chimeras 
 
Mice were subjected to split-dose irradiation, first with a 350 rad dose, followed 
by a 950 rad dose 24 hours later. 2 hours after the second dose of irradiation, mice were 
injected intravenously with 107 bone marrow cells from the femur and tibia of donor 
mice. The following four groups of chimeric mice were generated: WT → WT (CD45.1-
expressing WT cells into CD45.2-expressing WT mice), Aim2−/− → WT (CD45.2-
expressing Aim2−/− cells into CD45.1-expressing WT mice), WT → Aim2−/− (CD45.1-
expressing WT cells into CD45.2- expressing Aim2−/− mice) and Aim2−/− → Aim2−/−   
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Figure 2-1. Timeline for AOM and DSS treatment. 
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(CD45.2-expressing Aim2−/− cells into CD45.2-expressing Aim2−/− mice). The 
reconstitution rate evaluated 6 weeks after bone marrow transfer was determined by flow 
staining of CD45.1 and CD45.2 in blood leukocytes, which was at least 95%. 
 
 
Histology and Microscopy 
 
Tissues were fixed in 10% formalin, embedded in paraffin and sectioned. Colon 
tissues were stained with H&E. The number of proliferating cells in the intestinal 
epithelium was detected by immunoperoxidase staining for thymidine analog 5’-bromo-
2’deoxyuridine (BrdU). In brief, 1 mg/ml BrdU in PBS was injected intraperitoneally. 
Colon tissues were collected after 2 hours and fixed in 10% neutral buffered formalin and 
embedded in paraffin. Immunohistochemistry was performed using the in situ BrdU 
staining kit according to manufacturer’s instructions (BD Bioscience, 550803). Ki67 
(NBP1-40684, Novus Biologicals), AKT (4691, Cell Signaling Technology), p-AKT 
(Ser473; 4060, Cell Signaling Technology), and c-Myc (5605, Cell Signaling 
Technology) staining were performed using antibodies according to the manufacturers’ 
instructions. The number of Ki67- or BrdU-positive cells per crypt in each animal was 
counted (at least 18–20 crypts per mouse) blindly. Tissues were counterstained with 
hematoxylin. For staining of goblet cells, colon tissues were stained with PAS and Alcian 
blue. The number of goblet cells per crypt was counted blindly. For nLacZ analysis and 
GFP microscopy, intestinal tissues were perfused and fixed in 2% paraformaldehyde 
overnight, cryo-protected, and frozen in OCT. Sections were stained for -galactosidase 
or examined for GFP signal. For -galactosidase staining, frozen sections were washed in 
PBS for 5 min and incubated in the dark in standard -galactosidase substrate (5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal, 2 mM MgCl2, 
0.01% sodium deoxycholate, and 0.02% NP-40 in PBS) for 4 hours at 37 °C. Sections 
were then rinsed and counterstained by Nuclear Fast Red (Vector, H-3403). For TUNEL 
(terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling) 
staining of liver tissues after F. novicida infection, the staining was performed using In 
Situ Cell Death Detection Kit (11684817910) according to the manufacturer’s 
instructions (Sigma). 
 
Histological lesions were scored blindly by a pathologist for following the 
categories: inflammation severity, ulceration, hyperplasia and lesion area. Inflammation 
severity was assigned as follows: 0 = normal; 1 = mild (small, focal, or widely separated, 
mostly limited to lamina propria); 2 = moderate (multifocal mucosal inflammation, often 
extending to submucosa); 3 = marked (multifocal and coalescing to extensive 
inflammation with occasional transmural foci); 4 = severe (diffuse inflammation with 
transmural inflammation). Scores for ulceration were assigned as follows: 0 = normal (no 
ulcers); 1 = mild (1–2 ulcers, involving up to a total of 20 crypts); 2 = moderate (1–4 
ulcers, involving a total of 20–40 crypts); 3 = severe (more than 4 ulcers or over 40 
crypts). Hyperplasia scores were assigned as follows: 0 = normal; 1 = mild (Crypts 
elongated, normal epithelium); 2 = moderate (Crypts elongated with crowding of 
hyperchromatic epithelium, no branching of crypts); 3 = marked (Crypts 2-3 times 
normal thickness, hyperchromatic epithelium, reduced goblet cells, scattered 
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arborization); 4 = severe (Crypts 2-3 times normal thickness, marked hyperchromasia, 
few to no goblet cells, high mitotic index, frequent arborization). Scoring for lesion areas 
were assigned as follows: 0 = normal (0% involvement); 1 = minimal (less than 10% 
involvement); 2 = mild (10% to 25% involvement); 3 = moderate (25% to 50% 
involvement); 4 = marked (50% to 75% involvement); 5 = severe (over 75% 
involvement). 
 
 
Cell Culture and Stimulation 
 
Bone marrow-derived macrophages (BMDMs) were cultured for 6 days in 
DMEM containing 10% FBS, 30% L929 conditioned media and 1% penicillin and 
streptomycin, and seeded at a concentration of 1 × 106 cells onto 12-well plates. The next 
day, BMDMs were incubated in antibiotic–free media. BMDMs were stimulated with 
LPS (500 ng/mL; InvivoGen), Pam3CSK4 (1 μg/mL), gardiquimod (1 μg/mL; 
InvivoGen), Poly(I:C) (10 μg/mL; InvivoGen), or IFNβ (400 U/mL; PBL Assay Science). 
For transfection of poly(dA:dT), 0.25 μg or 1 ug of poly(dA:dT) (InvivoGen) was mixed 
with 0.3 mL of Xfect polymer in Xfect reaction buffer (Clontech Laboratories) for 10 
min and then added to BMDMs in Opti-MEM (ThermoFisher Scientific). For transfection 
of cGAMP, 1 μg of cGAMP (InvivoGen) was mixed with 0.3 mL of Xfect polymer in 
Xfect reaction buffer (Clontech Laboratories) for 10 min and then added to BMDMs in 
Opti-MEM (ThermoFisher Scientific). F. novicida was cultured and added to unprimed 
BMDMs at an indicated MOI for 20 hours. 50 μg/ml gentamicin was added after 4 hours 
of the infection. The MCMV Smith MSGV strain (VR-1399, American Type Culture 
Collection) was obtained from P.G. Thomas (St. Jude) and was used in experiments in 
Chapter 5. The MCMV strain (K181) was obtained from Edward S. Mocarski (Emory 
University School of Medicine) [87] and was used in experiments in Chapter 6. MCMV 
was added at an MOI of 10 for 10 hours. 
 
 
Cytokine Analysis 
 
Levels of cytokines were measured by ELISA according to the manufacturer’s 
instructions (IL-18 ELISA from eBioscience, IFN-β from BioLegend and all other 
cytokines were from Millipore).  
 
 
Immunoblotting Analysis 
 
Proteins from tissues were extracted using RIPA buffer supplemented with 
protease and phosphatase inhibitors (Roche). BMDMs samples were prepared as 
previously described [81, 83]. Prepared samples were then separated by SDS-PAGE and 
transferred to polyvinylidene difluoride membranes (Millipore). Membranes were 
blocked by 5% milk and incubated with primary antibodies overnight. The primary 
antibodies used were, caspase-1 p10 (sc-515, Santa Cruz), p-ERK (9101, Cell Signaling 
Technology), ERK (9102, Cell Signaling Technology), p-IBa (9241, Cell Signaling 
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Technology), IBa (9242, Cell Signaling Technology), STAT3 (9139, Cell Signaling 
Technology), p-STAT3 (9131, Cell Signaling Technology), HIF-1 (3716, Cell 
Signaling Technology), p-AKT Ser473 (9271, Cell Signaling Technology), AKT (4691, 
Cell Signaling Technology), p-PTEN (9554, Cell Signaling Technology), PTEN (9552, 
Cell Signaling Technology), c-Myc (5605, Cell Signaling Technology), caspase-1 (AG-
20B-0042, Adipogen), caspase-8 (ALX-804-447-C100, Enzo Life Sciences), cleaved 
caspase-8 (8592, Cell Signaling Technology), caspase-3 (9662, Cell Signaling 
Technology), cleaved caspase-3 (9661, Cell Signaling Technology), caspase-7 (9492, 
Cell Signaling Technology), cleaved caspase-7 (9491, Cell Signaling Technology), 
TRAIL (AF1121, R&D Systems), DR5 (MAB1540, R&D Systems), GAPDH (5174, Cell 
Signaling Technology), GSDMD (ab209845, Abcam), IL-18 (D046-3, MBL 
International), IL-1β (AF-401-NA, R&D Systems), and β-actin (8457, Cell Signaling 
Technology). Membranes were then incubated with HRP-conjugated secondary antibody 
for 1 hour and proteins were visualized using ECL substrate (ThermoScientific) or 
Luminata Forte Western HRP substrate (Millipore). Immunoblots were quantified using 
ImageJ in Chapter 5.  
 
 
Colon Organoid Culture 
 
Mouse colon stem cells were cultured as previously described with modifications 
[88]. Briefly, mice were perfused with prewarmed 30 mM EDTA in PBS. The colon was 
removed and rinsed with PBS. Colonic mucosa was scraped from the muscle layer and 
kept in 10 mM EDTA in PBS on ice and incubated in a shaker at 350 RPM for 15 min at 
4 °C. Dissociated colonic crypts were vigorously suspended. Cells were filtered through a 
70 mm cell strainer, mixed with Matrigel (BD Bioscience, 354230) and plated in 60 mm 
plates. The culture medium consisted of Advanced DMEM/F12 supplemented with B27, 
N2, N-Acetylcysteine, Gastrin (10 nM), and growth factors, including 50 ng/ml EGF, 1 
mg/ml R-spondin1, 100 ng/ml Noggin, 100 ng/ml FGF10, and Wnt3A conditioned media 
[89]. 
 
 
Real-time Quantitative PCR 
 
RNA was extracted using TRIzol reagent (Life Technologies). Isolated RNA was 
reverse transcribed into cDNA using the First-Strand cDNA Synthesis Kit (Life 
Technologies). Real-time quantitative PCR (qPCR) was performed on an ABI 7500 real-
time PCR instrument with 2× SYBR Green (Applied Biosystems). Primer sequences in 
Table 2-1.  
 
 
Universal Sequencing of Gut Microbiota 
 
Genomic DNA from feces was extracted with the QiAamp DNA stool Mini Kit 
(QIAGEN) and used for 16S rRNA gene sequencing. Libraries were prepared by 
amplification of the 16S v4 domain according to the manufacturer’s instructions (Bioo   
 13 
Table 2-1. Real-time qPCR primer sequences. 
 
Target Primer sequence 
Sting Forward: 5’-CAT TGG GTA CTT GCG GTT-3’ 
 Reverse: 5’-CTG AGC ATG TTG TTA TGT AGC-3’ 
Aim2 Forward: 5’-GAT TCA AAG TGC AGG TGC GG-3’ 
 Reverse: 5’-TCT GAG GCT TAG CTT GAG GAC-3’  
Gapdh Forward: 5’-CGT CCC GTA GAC AAA ATG GT-3’ 
 Reverse: 5’-TTG ATG GCA ACA ATC TCC AC-3’ 
Il17a Forward: 5’-TCC AGA AGG CCC TCA GAC TA-3’ 
 Reverse: 5’-ACA CCC ACC AGC ATC TTC TC-3’ 
Il22 Forward: 5’-TCC GAG GAG TCA GTG CTA AA-3’ 
 Reverse: 5’-AGA ACG TCT TCC AGG GTG AA-3’ 
Il23p19 Forward: 5’-GGT GGC TCA GGG AAA TGT-3’ 
 Reverse: 5’-GAC AGA GCA GGC AGG TAC AG-3’ 
Ifnb Forward: 5’-GCC TTT GCC ATC CAA GAG ATG C-3’ 
 Reverse: 5’-ACA CTG TCT GCT GGT GGA GTT C-3’ 
Ifng Forward: 5’-GCA TCT TGG CTT TGC AGC T-3’ 
 Reverse: 5’-CCT TTT TCG CCT TGC TGT TG-3’ 
Tgfb1 Forward: 5’-CTC CCG TGG CTT CTA GTG C-3’ 
 Reverse: 5’-GCC TTA GTT TGG ACA GGA TCT G-3’ 
Tgfb2 Forward: 5’-TCG ACA TGG ATC AGT TTA TGC G-3’ 
 Reverse: 5’-CCC TGG TAC TGT TGT AGA TGG A-3’ 
Il10 Forward: 5’-GCT CTT ACT GAC TGG CAT GAG-3’ 
 Reverse: 5’-CGC AGC TCT AGG AGC ATG TG-3’ 
Muc2 Forward: 5’-GCT GAC GAG TGG TTG GTG AAT G-3’ 
 Reverse: 5’-GAT GAG GTG GCA GAC AGG AGA C-3’ 
Muc3 Forward: 5’-CGT GGT CAA CTG CGA GAA TGG-3’ 
 Reverse: 5’-CGG CTC TAT CTC TAC GCT CTC C-3’ 
Muc4 Forward: 5’-CAG CAG CCA GTG GGG ACA G-3’ 
 Reverse: 5’-CTC AGA CAC AGC CAG GGA ACT C-3’ 
cMyc Forward: 5’-TCT CCA CTC ACC AGC ACA ACT ACG-3’ 
 Reverse: 5’-ATC TGC TTC AGG ACC CT-3’ 
S100a9 Forward: 5’-GGT GGA AGC ACA GTT GGC A-3’ 
 Reverse: 5’-GTG TCC AGG TCC TCC ATG ATG-3’ 
Snrpd1 Forward: 5’-CAG CAT GAA CAC ACA CCT TAA AG-3’ 
 Reverse: 5’-GCC TCG AAT ACT CAA TGT TTC CA-3’ 
Dbf4 Forward: 5’-AAT AAG ATA CAG TGT CGG GTC CC-3’ 
 Reverse: 5’- GTC CTT CTG GAA ATT GGG CTC-3’ 
Il18 Forward: 5’-GCC TCA AAC CTT CCA AAT CA-3’ 
 Reverse: 5’-TGG ATC CAT TTC CTC AAA GG-3’ 
Il1b Forward: 5’-GAC CTT CCA GGA TGA GGA CA-3’ 
 Reverse: 5’-AGC TCA TAT GGG TCC GAC AG-3’ 
Trail Forward: 5’- ACC TCA GCT TCA GTC AGC ACT TC -3’ 
 Reverse: 5’- TGT AAG TCA CAG CCA CAG ACA CAG -3’  
Dr5 Forward: 5’- AGT GTG TCT CCA AAA CGG -3’ 
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Table 2-1. Continued. 
 
Target Primer sequence 
 Reverse: 5’- AAT GCA CAG AGT TCG CAC T -3’ 
b-actin Forward: 5’-CAG CTT CTT TGC AGC TCC TT-3’ 
 Reverse: 5’-CAC GAT GGA GGG GAA TAC AG-3’ 
Hprt Forward: 5’-CTC ATG GAC TGA TTA TGG ACA GGA C-3’ 
 Reverse: 5’-GCA GGT CAG CAA AGA ACT TAT AGC C-3’ 
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Scientific Corporation). Paired-end 150 cycle sequencing was performed on a MiSeq 
using 300 cycle v2 sequencing kits according the manufacturer’s instructions (Illumina) 
with the following modifications: a phiX library was spiked in at ~10%, and library 
specific sequencing primers were added to the Illumina primer wells as specified by the 
manufacturer (Bioo Scientific Corporation). Primers targeting the 16S V4 region were 
aligned to the full set of sequences from the Greengenes database v13.5 [90] using 
exonerate [91]. Each sequence was truncated to include only the V4 region, the primer-
matching regions and an additional 40 bases on either side. Duplicate V4 regions were 
removed from the dataset. All taxa labels from the removed duplicates were associated 
with the remaining representative V4 region sequence. Reads from each sample were 
aligned exhaustively to the non-redundant V4 sequences using USEARCH [92] allowing 
a minimum sequence identity of 90%. All taxon labels associated with the top-scoring V4 
region(s) were used to determine the taxon assignment of each read. The highest 
resolution non-conflicting taxon from all taxa associated with the top-scoring V4 region 
was assigned as the taxa for a read. Relative proportions of microbial taxa for each 
sample were assembled from the highest resolution sequence counts into a matrix with 
samples as columns and taxa as rows with proportions in cells. Columns were also 
assigned to either a WT or Aim2−/− group. All relative proportions were transformed to 
near normality with a shifted logit-p transformation [86]. Unpaired T-test with unequal 
variance for the normalized proportions and a two-factor ANOVA model was used to 
investigate significant taxa. Transformed values were then normalized for each taxa to 
produce a signal to noise ratio [86]. Signal to noise ratios are depicted in a heatmap plot 
and Principal Component Analysis (PCA) were generated with Spotfire (Tibco software 
Inc). 
 
 
IncuCyte Analysis 
 
BMDMs were seeded at a concentration of 1 × 106 cells onto 12-well plates. The 
next day, BMDMs were stimulated and incubated with 100 nM of cell-impermeable 
DNA-binding fluorescent dye Sytox Green (S7020, Life Technologies) to stain dead 
cells. Cell death was monitored in real-time using a two-color IncuCyte Zoom in-
incubator imaging system (Essen Biosciences). Nuclear-ID (ENZ-52406, Enzo Life 
Sciences) was added at the last time point to stain live and dead cells for the total cell 
number [93]. Resulting images were analyzed using IncuCyte S3 software. Cell death 
was presented as a percentage of Sytox Green+ cells to the total cell number. Experiments 
were conducted with three replicates for each experimental condition and nine image 
fields per well. 
 
 
Flow Cytometry 
 
For intracellular cytokine staining, cells were processed as previously described 
[94]. The following monoclonal antibodies were diluted 1:300 and used for flow 
cytometry cellular analyses: CD3 (17A2), CD4 (RM4-5), CD11b (M1/70), CD19 (1D3), 
CD8a (53-6.7), IFN-γ (XMG1.2) and IL-17A (eBio17B7) from eBioscience, CD4 
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(GK1.5), TCR-β (H57-597), CD11c (N418), Gr1 (RB6-815), F4/80 (BM8), IL-6 (MP5-
20F3) and TNF (MP6-XT22) from BioLegend and CD8a (53-6.7) from Sony. Flow 
cytometry data were acquired on FACSCalibur (BD) and were analyzed with FlowJo 
software (FlowJo, LLC and Illumina, Inc). 
 
 
Statistical Analysis 
 
GraphPad Prism software was used for data analysis. Data are shown as mean ± 
SEM. Statistical significance was determined by performing t tests (two-tailed), one-way 
ANOVA or log-rank test. P<0.05 was considered to be statistically significant where *p < 
0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
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CHAPTER 3.    STING MEDIATES PROTECTION AGASINT COLON CANCER 
BY REGULATING COLON INFLAMMATION 
 
 
Introduction 
 
Colon cancer is the third most common malignant tumor in the United States, 
with 1.5 million new cases being diagnosed each year [95]. Clinical studies have shown 
that patients diagnosed with inflammatory bowel diseases have a greater risk of 
developing colon cancer compared to healthy individuals [96]. Pattern recognition 
receptors are key initiators of inflammation, which have been shown to be involved in 
colitis-associated colon cancer development [97]. 
 
Cytosolic nucleic acid receptors mediate the detection of DNA and RNA 
molecules within the cell and provide robust host immune defense against intracellular 
pathogens and protection against autoimmune diseases [98]. STING is a cytoplasmic 
receptor for cyclic dinucleotides and an adaptor for other DNA sensors [12, 15, 17, 19, 
99, 100]. The upstream DNA sensors, which signal through STING include cGAS, IFI16 
and DDX41 [12, 99, 100], highlighting an important function for STING in governing 
multiple DNA recognition pathways. STING recruits TBK1 to activate IRF3, the latter of 
which translocates into the nucleus in a dimeric form and induces transcription of type I 
interferons. 
 
Since its discovery, STING has been shown to contribute to the host defense 
against viral, bacterial and eukaryotic pathogens [101]. Whether STING plays a role 
during the development of colon cancer or other types of cancer is unknown. Evidence 
for a role of a number of nucleic acid sensors in tumorigenesis is emerging. Our group 
and others have previously shown that nucleotide-binding domain, leucine-rich repeat 
containing protein 3 (NLRP3), a proposed sensor of RNA or DNA:RNA hybrid in the 
cytoplasm of a cell [102-104], mediates protection against colon cancer development by 
modulating IL-18 production [27, 29]. The double-stranded DNA sensor, AIM2, and the 
double-stranded RNA sensor, RIG-I, are downregulated in patients with colorectal cancer 
and hepatocellular carcinoma, respectively, and reduced expression of these proteins are 
associated with increased mortality in these patients [26, 105]. Expression of LGP2, a 
negative regulator of RIG-I, promotes the survival of colon tumor and other cancer cell 
lines [106]. In addition, mice lacking the DNA sensor, Ku70, in combination with the 
p53R172P mutation, develop spontaneous colonic inflammation and colon cancer [107]. 
These studies indicate that nucleic acid sensors may play a critical function in the 
regulation of tumorigenesis. 
 
                                                 
 Adapted with permission. Zhu Q., Man S.M., Gurung P., Liu Z., Vogel P., Lamkanfi 
M., Kanneganti T.D. (2014). Cutting Edge: STING mediates protection against colorectal 
tumorigenesis by governing the magnitude of intestinal inflammation. Journal of 
Immunology. 193(10):4779-82. Copyright 2014. The American Association of 
Immunologists, Inc. 
 18 
In this study, we show that STING-deficient mice (Stinggt/gt) are highly 
susceptible to tumor formation in a model of colitis-associated colorectal cancer. The 
absence of STING leads to excessive colon inflammation during early stages of tumor 
development, characterized by elevated levels of colonic and circulating pro-
inflammatory cytokines and an increased number of proliferative intestinal epithelial 
cells. In addition, we observe increased phosphorylation of NF-κB and STAT3 in 
STING-deficient mice, indicating a role for STING in governing the suppression of 
transcription factor activities during intestinal inflammation. Overall, these results 
underscore a critical role for STING in mediating host protection against colorectal 
tumorigenesis. 
 
 
Results and Discussion 
 
STING is expressed in a variety of tissues and organs in mice (Figure 3-1A). The 
spleen and small and large intestines expressed the highest levels of STING mRNA 
(Figure 3-1A). To investigate the role of STING in colon tumor development, we 
utilized a colitis-associated colon cancer model to induce colon tumorigenesis in mice. 
We intraperitoneally injected AOM into WT and Stinggt/gt mice followed by three rounds 
of DSS treatment. After 80 days post-AOM injection, we observed that Stinggt/gt mice had 
significantly increased tumor burden compared to WT controls (Figure 3-1B–C). 
Although the number of tumors doubled in Stinggt/gt mice, the size of tumors in Stinggt/gt 
and WT mice was similar (Figure 3-1D). Histological analysis revealed that Stinggt/gt 
mice exhibited more severe pathological damage after tumor development, characterized 
by increased colonic inflammation and hyperplasia (Figure 3-1E–G). Histological 
observations were quantified and these scores revealed that Stinggt/gt mice showed 
enhanced intestinal pathology compared to WT mice (histological scores: 17.6 ±1.2 for 
Stinggt/gt and 10.6 ± 0.9 for WT; Figure 3-1F). Notably, the incidence of dysplasia was 
observed exclusively in Stinggt/gt mice, with 75% of the colon samples from Stinggt/gt mice 
showing hallmarks of low grade (50% of the samples) or high grade (25%) dysplasia 
(Figure 3-1H). Therefore, these data suggest a crucial role for STING in suppressing 
colorectal tumorigenesis in colitis-associated colon cancer.  
 
We observed that Stinggt/gt mice lost significantly more body weight than WT 
mice (Figure 3-2A). Indeed, the colon length was greatly reduced in Stinggt/gt mice on 
Day 14 (Figure 3-2B). H&E staining revealed an increase in cellular infiltration, crypt 
thickness and hyperchromatin in colon tissues of Stinggt/gt mice on Day 14 (Figure 3-2C). 
In agreement, all of the histologic parameters assessed – inflammation, ulceration and 
hyperplasia – were significantly higher in Stinggt/gt mice compared to WT mice       
(Figure 3-2D–E). To assess whether STING mediates neoplastic changes that predispose 
the host to increased tumorigenic events, we performed Ki-67 staining on colon tissue 
sections and quantified the magnitude of intestinal epithelial proliferation. In line with 
our histological analysis, the colon of Stinggt/gt mice had significantly increased numbers 
of Ki-67 positive cells per crypt (58.7 ± 2.1; n=137) compared to WT mice (39.6 ± 1.3; 
n=153; P<0.0001) on Day 14 (Figure 3-2F). Taken together, these results suggest that  
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Figure 3-1. STING is critical for mediating protection against colon tumor 
development. 
(A) Relative Sting mRNA levels in different tissues of WT mice. (B) Colons from WT 
and Stinggt/gt mice on Day 80 post-AOM injection. (C) Tumor number and (D) size in WT 
and Stinggt/gt mice. (E) Colon tissue sections by H&E staining. Magnification: 20×. (F) 
Total histological scores and (G) scores for different parameters on Day 80. (H) 
Percentage of WT and Stinggt/gt mice with dysplasia. *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001. (two-tailed t test [B–D, F, and G]). Data are from one experiment 
representative of three independent experiment (B and D–H) or pooled from three 
independent experiments (A and C; mean and SEM in C, D, F and G). 
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Figure 3-2. STING dampens early intestinal damage and overt proliferation. 
(A) Body weight changes in WT and Stinggt/gt mice during early stages of colorectal 
tumorigenesis. (B) Colon length on Day 14 post-AOM injection. (C) H&E staining of 
colon tissue sections on Day 14. Magnification: 10×. (D) Total histological scores and 
(E) scores for different parameters on Day 14. (F) The number of Ki-67-positive cells in 
each crypt of each animal on Day 14 (at least 27 crypts per mouse). WT n=5; Stinggt/gt 
n=5. Data are mean ± SEM of two independent experiments. NS, not statistically 
significant; **p<0.01; ***p<0.001; ****p<0.0001. (two-tailed t test [A, B, D, E and F]). 
Data are from one experiment representative of two independent experiment (C, D, E and 
F) or pooled from two independent experiments (A and B; mean and SEM in A, B, D, E 
and F). 
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STING plays an important function in controlling disease initiation and susceptibility to 
hyper-proliferation during early stages of colitis-associated colon cancer. 
 
Since inflammation is one of the most important drivers in the development of 
colon cancer [97], we hypothesized that STING is controlling inflammation during early 
stages of AOM-DSS treatment, which ultimately determines host susceptibility to 
colorectal tumorigenesis. To analyze the magnitude of colonic inflammation in Stinggt/gt 
mice, we measured levels of the pro-inflammatory cytokines IL-6 and CXCL1 (KC) on 
Day 14 post-AOM injection. We observed a significant increase in the levels of IL-6 and 
KC in colon tissues of Stinggt/gt mice compared to WT mice (Figure 3-3A). We 
confirmed this finding and observed elevated levels of circulating IL-6 and KC in the 
serum of Stinggt/gt mice (Figure 3-3B). Consistently, we found elevated phosphorylation 
of ERK and IκBα in colon tissues of Stinggt/gt mice compared to WT mice on Day 14 
(Figure 3-3C). Previous reports have shown that myeloid cell-derived IL-6 signals 
through IL-6R and gp130 to activate cytoplasmic STAT3 in intestinal epithelial cells 
[108, 109]. STAT3 is frequently activated in pre-malignant and cancer cells to promote 
colon tumorigenesis by amplifying inflammation and tumorigenic transformation [110]. 
Indeed, colon tissues from Stinggt/gt mice showed increased STAT3 phosphorylation 
compared to WT mice (Figure 3-3D). We also measured production of type I IFN by 
testing the level of IFN-β after 14 days post-AOM injection and detected only basal 
levels of IFN-β in colon tissues from WT or Stinggt/gt mice (Figure 3-4A). 
 
Caspase-1-mediated release of IL-18 following inflammasome activation has been 
shown to play a protective role in preventing AOM-DSS-induced colitis and colitis-
associated colorectal tumorigenesis [27-29, 111]. Mice lacking caspase-1 or IL-18 
exhibited elevated tumor burden in the colon with increased levels of pro-inflammatory 
cytokines during AOM-DSS-induced colon tumorigenesis [29]. We found reduced levels 
of caspase-1 activation and IL-18 release in colon tissues of Stinggt/gt mice compared to 
WT mice after 14 days (Figure 3-4B–C). Therefore, it is possible that the crosstalk 
between STING and caspase-1 could mediate protection against colon tumorigenesis at 
the intestinal barrier. Indeed, recent studies suggest that activation of the STING pathway 
leads to assembly of NLRP3 inflammasome [112, 113], potentially by inducing 
lysosomal cell death and potassium efflux [112]. It is possible that STING induces 
NLRP3 inflammasome activation in the colon leading to caspase-1-mediated protective 
IL-18 release. These findings highlight that STING restricts NF-κB and STAT3 signaling 
pathways by activating inflammasome responses to control colon inflammation and 
tumorigenesis. 
 
The gut microbiota plays a critical role in modulating susceptibility to colorectal 
cancer. Dysbiosis is associated with increased susceptibility to colitis and colon cancer 
development [97]. To investigate whether an altered gut microbiota profile contributed to 
the elevated incidence of colorectal tumorigenesis in Stinggt/gt mice, we performed real-
time qPCR analysis to detect the abundance of five major intestinal bacterial populations 
from WT and Stinggt/gt mice. We found that WT and Stinggt/gt mice harbored similar levels 
of Prevatollaceae, Bacteroides, mouse intestinal Bacteroides (MIB), segmented 
filamentous bacteria (SFB) and TM7 (Figure 3-4D–H). Therefore, it is unlikely that   
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Figure 3-3. STING suppresses overt colon inflammation during tumor 
development.  
(A and B) Levels of IL-6 and KC in colon tissues (A) and serum (B) on Day 14 post-
AOM injection. (C and D) Phosphorylation of ERK, IκBa (C) and STAT3 (D) in colon 
tissues on Day 14, quantified by densitometric analysis. Data are mean ± SEM of two 
independent experiments. *p<0.05; **p<0.01; ***p<0.001. (two-tailed t test [A and B]). 
Data are from one experiment representative of two independent experiment (C and D) or 
pooled from two independent experiments (A and B; mean and SEM in A–D). 
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Figure 3-4. The type I IFNs, caspase-1 and gut microbiota profile of WT and 
Stinggt/gt mice. 
(A) Levels of IFN-β in colon tissues from WT and Stinggt/gt mice after 14 days post-AOM 
injection were measured by ELISA. (B) Caspase-1 cleavage in colon lysates from WT 
and Stinggt/gt mice on Day 14.  (C) Level of IL-18 in colon tissues on Day 14. (D–H) 
Levels of Prevatollaceae, Bacteroides, MIB, SFB and TM7 in untreated WT and Stinggt/gt 
mice. Data are shown as mean ± SEM of two independent experiments. NS, not 
statistically significant; ***p<0.001.  
  
 24 
differences in these bacterial populations contributed to the protective role of STING 
during colon cancer development. 
 
During AOM-DSS-induced colon tumorigenesis, STING itself or in concert with 
an upstream DNA sensor may recognize either cytosolic DNA in tumor cells, or DNA 
upon DNA damage [114], or DNA derived from dying cells during intestinal barrier 
damage or colon tumor cells [115]. In addition, oxidative DNA damage has been shown 
to accumulate in intestinal epithelial cells and activate STING signaling [116, 117]. It is 
possible that recognition of self-DNA by STING mediates inflammasome activation, 
which suppresses colon inflammation and reduces the likelihood of uncontrolled 
inflammation leading to tumorigenesis. 
 
Overall, our results underscore a novel role for STING in modulating activation 
of NF-κB and STAT3 signaling and production of IL-18 during the development of colon 
cancer. These inflammatory mediators may modulate the tumorigenic properties of 
intestinal cells, which ultimately regulate proliferation and tumorigenesis. Collectively, 
our data indicate that STING plays a critical role in mediating protection against 
inflammation-associated colon cancer development. Therapeutic modulation of STING in 
susceptible individuals may have the potential to prevent and treat colon cancer. 
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CHAPTER 4.    ROLE OF THE DNA SENSOR AIM2 IN COLON CANCER 
 
 
Introduction 
 
Colorectal cancer is a leading cause of cancer-related deaths, with 160,000 cases 
being diagnosed annually in the USA [118]. Mutations in the gene encoding AIM2 are 
frequently identified in patients with colorectal cancer. A previous study has shown that 
over 50% of tumors from patients with small bowel cancer have frameshift mutations in 
the gene encoding AIM2 [119]. Further genetic evidence has shown that frameshift and 
missense mutations are targeted to the coding regions of the gene encoding AIM2 in 
colon cancer tissues and cell lines [38, 39]. These include frameshift mutations in the 
A10 repeat of exon 6, a deletion mutation in the A6 repeat of exon 5, and a 
nonsynonymous nucleotide exchange within exon 2 of the gene encoding AIM2 – all of 
which were identified in tumor tissues of patients with colorectal cancer with a high level 
of microsatellite instability associated with deficiency in mismatch repair [38]. Analysis 
of 414 colorectal tumors and matching control tissues further revealed that 67% of the 
tumors displayed reduced expression of the gene encoding AIM2 relative to control 
tissues [26]. Nearly 50% of patients who completely lacked expression of the gene 
encoding AIM2 in their tumor cells die from their cancer within five years of diagnosis, 
whereas over 70% of patients whose tumor cells retained some expression survived 
beyond five years after their diagnosis [26]. A better understanding of the biological 
function of AIM2 in colorectal cancer is key to identifying therapies that could be used in 
the treatment of this disease. 
 
AIM2 is a cytosolic dsDNA receptor which contributes to the host defense against 
bacterial and viral pathogens, such as Francisella tularensis and vaccinia virus, 
respectively [32-35, 41, 42]. We previously identified that infection by the cytosolic 
bacterium F. novicida activates the transcription factor IRF1, which induces production 
of interferon-inducible GTPases called GBPs [44]. GBPs attack and kill bacteria in the 
cytoplasm, resulting in the liberation of bacterial DNA for recognition by AIM2 [44, 45]. 
Upon binding of dsDNA in the cytoplasm of infected cells, AIM2 recruits the adaptor 
protein ASC to assemble an inflammasome complex that activates caspase-1, a cysteine 
protease that induces pyroptosis and mediates the cleavage of the inflammatory cytokines 
IL-1 and IL-18. Structural analysis of AIM2 revealed that the HIN200 domain binds 
dsDNA, whereas the pyrin domain recruits ASC [120]. DNA accumulated in 
keratinocytes also activates the AIM2 inflammasome to drive the release of IL-1β in 
lesions of patients with psoriasis [121], suggesting that AIM2 has the capacity to 
recognize damage-associated molecular patterns released by the cell. Activation of AIM2 
                                                 
 Adapted with open access permission. Man S.M.*, Zhu Q.*, Zhu L.*, Liu Z.*, Karki R., 
Malik A., Sharma D., Li L., Malireddi R.K., Gurung P., Neale G., Olsen S.R., Carter 
R.A., McGoldrick D.J., Wu G., Finkelstein D., Vogel P., Gilbertson R.J., Kanneganti 
T.D. (2015). Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. 
Cell. 162(1):45-58. (* Co-first author) 
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must, therefore, be tightly regulated to allow clearance of pathogens while maintaining 
homeostasis to prevent the development of autoimmune conditions.  
 
In this study, we found that AIM2-deficient (Aim2–/–) mice developed more 
tumors in the colon following AOM and DSS-induced colitis-associated tumorigenesis. 
Unlike its role in the host defense against infection, AIM2 protected against 
tumorigenesis by controlling intestinal epithelial cell proliferation via a mechanism 
independent of inflammasomes and inflammatory mediators. Upon dyregulated Wnt 
signaling, AIM2 suppressed expansion of tumor-initiating intestinal stem cells lining the 
base of the crypt. Remarkably, reciprocal exchange of the gut microbiota between healthy 
WT mice and Aim2–/– mice reduced the susceptibility of Aim2–/– mice to colorectal 
tumorigenesis. These findings revealed a role for AIM2 and its synergy with gut 
microbiota in the development of colorectal cancer. 
 
 
Results 
 
 
The DNA Receptor AIM2 Is Required to Prevent Colorectal Cancer 
 
Mutations in the gene encoding AIM2 are associated with colorectal cancer and 
reduced expression of this gene is linked to increased mortality in humans [122-125]. In 
mice, the gene encoding AIM2 was widely expressed in the intestine, especially in the 
colon (Figure 4-1A), which suggested a role for AIM2 in regulating homeostasis in the 
gastrointestinal tract. To investigate the role of AIM2 in colorectal cancer, we used an 
established model of colitis-associated colorectal tumorigenesis whereby mice were 
injected intraperitoneally with AOM, followed by three rounds of DSS treatment  
(Figure 2-1). Expression of the gene encoding AIM2 was drastically reduced in the colon 
of WT mice 14 or 80 days after injection of AOM (Figure 4-1B–C). 
 
We treated cohorts of WT and Aim2–/– mice with AOM followed by DSS and 
examined the development of colon tumors after 80 days. We found that Aim2–/– mice 
developed significantly increased numbers and size of tumors throughout the middle and 
distal colon compared with WT mice (Figure 4-1D–F). Aim2–/– mice also tended to lose 
more body weight over the course of DSS treatment after injection of AOM           
(Figure 4-1G). Histopathological analysis revealed that Aim2–/– mice exhibited increased 
hyperplasia in the proximal, middle and distal colon (Figure 4-1H). Low-grade dysplasia 
was restricted to tumor-bearing WT mice whereas both low- and high-grade dysplasia 
was observed in Aim2–/– mice (Figure 4-1I–J). These results suggested that AIM2 
mediated protection against colorectal tumorigenesis. 
 
 
AIM2 Controls Tumor Development Independently of Inflammasomes 
 
AIM2 is a dsDNA receptor that contributes to the host defense against bacterial 
and viral pathogens by inducing inflammasome responses, including the production of  
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Figure 4-1. AIM2 prevents colitis-associated colorectal tumorigenesis. 
(A) Relative expression of the gene encoding AIM2 in tissues of WT mice. (B) Relative 
expression of the gene encoding AIM2 in colon tissues of untreated WT mice or WT 
mice 14 days after injection of AOM. (C) Relative expression of the gene encoding 
AIM2 in colon tissues of untreated WT mice or WT mice 80 days after injection of 
AOM. (D) Colon tumors in WT and Aim2–/– mice 80 days after injection of AOM. (E and 
F) Number and size of colon tumors in WT (n = 34) and Aim2–/– (n = 27) mice. (G) Body 
weight change of mice pooled from six independent experiments. (H) Histological scores 
80 days after injection of AOM. (I) Percentages of mice with dysplasia 80 days after 
injection of AOM. (J) H&E staining of colon tumors. Original magnification, 10. *p < 
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; NS, not statistically significant (two-
tailed t test [B, C, E, F, and H] or one-way ANOVA [G]). Data are from two (A–C) or six 
independent experiments (D–J; mean and SEM in B, C, E, F, G, and H). 
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IL-18. We and others have previously shown that IL-18 induced by the related 
inflammasomes, NLRP3 or PYRIN inflammasome, is required for protection against 
colitis and colitis-associated tumorigenesis [27-29, 111]. To investigate the molecular 
mechanism underpinning AIM2-dependent protection against colorectal tumorigenesis, 
we first examined whether there was a lack of inflammasome signaling in Aim2–/– mice 
that could be responsible for their increased susceptibility to tumorigenesis. We analyzed 
the levels of caspase-1 processing in the colon of WT and Aim2–/– mice and found similar 
levels of caspase-1 activation 14 days after injection of AOM (Figure 4-2A). We also 
detected similar levels of IL-18 in the colon tissues and serum of untreated WT and 
Aim2–/– mice or in WT and Aim2–/– mice 8, 14 or 80 days after injection of AOM  
(Figure 4-2B). To further confirm these results, we measured IL-1β and found similar 
levels of this inflammasome-dependent cytokine in the colon tissues of untreated WT and 
Aim2–/– mice or in WT and Aim2–/– mice 14 or 80 days after injection of AOM      
(Figure 4-2C).  
 
Although AIM2 functioned independently of the inflammasome in protection 
against colonic tumorigenesis, we investigated whether other inflammatory mediators 
might be playing a role in the absence of AIM2 that could have accelerated the 
progression of colorectal cancer. Shortening of the colon during DSS treatment is a 
hallmark of inflammation. However, we observed similar colon lengths in WT and Aim2–
/– mice 14 or 80 days after injection of AOM (Figure 4-2D). The NF-κB pathway is a 
major driver of inflammation. To this end, we analyzed phosphorylation of ERK and 
IκBα in colon tissues of WT and Aim2–/– mice following AOM-DSS treatment. Both 
groups of mice exhibited similar levels of phosphorylated ERK and IκBα (Figure 4-2E). 
In agreement, the levels of pro-inflammatory cytokines IL-6, TNF and G-CSF and the 
chemokine KC were not significantly increased in Aim2–/– mice 14 days after injection of 
AOM when compared with WT mice (Figure 4-2F). However, an increase in the levels 
of TNF, G-CSF and KC were observed 80 days after injection of AOM (Figure 4-2F). 
We further assessed the levels of cytokines IL-22, IL-23p19, IFN-β, IFN-γ and IL-17A. 
Using qRT-PCR analysis, we found that the expression of genes encoding these 
cytokines was similar in colon tissues of untreated WT and Aim2–/– mice and in colon 
tissues of WT and Aim2–/– mice 14 days after injection of AOM (Figure 4-3A–B). 
However, Aim2–/– mice had an increase in the expression of the gene encoding IL-10 14 
days after injection of AOM (Figure 4-3C). Furthermore, we found that the expression of 
genes encoding TGF-β1 and TGF-β2 was similar in colon tissues of untreated WT and 
Aim2–/– mice and in WT and Aim2–/– mice 14 days after injection of AOM (Figure 4-3C).  
 
We used an automated hematology analyzer to determine the number and influx 
of circulating white blood cells from the peripheral blood of WT and Aim2−/− mice. We 
observed similar levels of neutrophils, lymphocytes, monocytes, eosinophils and 
basophils and total white blood cells in the blood of WT and Aim2−/− mice 14 or 80 days 
after injection of AOM (Figure 4-3D). While there was an increase in circulating 
lymphocytes in Aim2−/− mice on day 80 compared with day 14, the proportion of IFN-γ-, 
IL-17- or TNF-expressing CD4+ or CD8+ T cells in the MLNs and spleens was similar in 
WT and Aim2–/– mice (Figure 4-2G). In addition, the prevalence of splenic and MLN- 
associated CD11b+ cells producing TNF or IL-6 was also similar in WT and Aim2–/– mice   
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Figure 4-2. AIM2 governs colorectal tumorigenic susceptibility independently of 
inflammasomes and a number of inflammatory mediators. 
(A) Caspase-1 processing in colon lysates from WT and Aim2–/– mice 14 days after 
injection of AOM. (B) Levels of IL-18 in the colon tissues and sera. (C) Levels of IL-1b 
in colon tissues. (D) The lengths of colon from WT and Aim2–/– mice 14 days after 
injection of AOM. (E) Immunoblot analysis (left) and densitometric quantification of 
band intensity of phosphorylated and total ERK and IκBa (right) in colon tissues of WT 
and Aim2–/– mice 14 days after injection of AOM. (F) Levels of IL-6, TNF, G-CSF, and 
KC in colon tissues. (G) Percentages of CD4+ cells, CD4+ cells expressing IFN-γ or IL-
17, CD8+ cells, CD8+ cells expressing IFN-γ, CD11b+ cells, and CD11b+ cells expressing 
IL-6 or TNF. *p < 0.05; **p < 0.01; NS, not statistically significant (two-tailed t test [B–
D, F, and G]). Data are from one experiment representative of two independent 
experiment (A–C and G) or pooled from three independent experiments (D–F; mean and 
SEM in B–G). 
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Figure 4-3. AIM2 governs colorectal tumorigenic susceptibility independently of 
the magnitude of inflammation. 
(A) Relative expression of genes encoding IL-22 and IL-23p19 in colon tissues of 
untreated WT and Aim2–/– mice or in WT and Aim2–/– mice 14 days after injection of 
AOM. (B) Relative expression of genes encoding IFN-β, IFN-γ and IL-17A in colon 
tissues of untreated WT and Aim2–/– mice or in WT and Aim2–/– mice 14 days after 
injection of AOM. (C) Relative expression of genes encoding TGFβ1, TGFβ2 and IL-10 
in colon tissues of untreated WT and Aim2–/– mice or in WT and Aim2–/– mice 14 days 
after injection of AOM. (D) Automated hematology analyzer of white blood cell (WBC) 
populations in the whole blood of untreated WT and Aim2–/– mice and WT and Aim2–/– 
mice 14 or 80 days after injection of AOM. *p < 0.05; NS, not statistically significant; 
two tailed t test. Data are from one experiment (D) or pooled from two independent 
experiments (A–C, mean and SEM in A–D).  
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(Figure 4-2G). The prevalence of total CD11b+ cells was, however, elevated in the 
spleen, but not in the MLN. The modest increases in some inflammatory parameters in 
mice lacking AIM2 suggested a role for an immunological component in shaping tumor 
development in these mice. Identification of a role for AIM2 independently of classical 
inflammasome signaling and a number of other inflammatory mediators also suggested, 
at least in parts, alternative functions for AIM2 in the regulation of gastrointestinal 
homeostasis during colorectal tumorigenesis. 
 
 
AIM2 Controls Proliferation of Enterocytes 
 
Given that the increased susceptibility to tumor development in Aim2–/– mice 
could not be explained by differences in inflammasome activity or by a number of 
inflammatory mediators, we asked whether AIM2 regulated cellular proliferation or death 
following exposure to AOM and DSS. We used immunohistochemistry techniques to 
identify proliferative cells in the colon of WT and Aim2–/– mice. We observed a 
significantly higher number of BrdU+ proliferative cells per crypt in the colon of Aim2–/– 
mice 14, but not 8, days after injection of AOM (Figure 4-4A). We confirmed these 
findings and found a significantly higher number of Ki67+ cells per crypt in the intestinal 
epithelium of Aim2–/– mice 14 days after injection of AOM compared with WT mice, 
whereas no difference was observed in untreated WT and Aim2–/– mice (Figure 4-4A). 
Further, we used microarray analysis to screen for genes expressed differentially in colon 
tissues of WT and Aim2–/– mice 14 days after injection of AOM. Using this approach, we 
indeed identified increased expression of genes encoding molecules involved in cell 
proliferation in Aim2–/– mice relative to their expression in WT mice (Figure 4-4B). 
These included genes encoding S100A9 and BIRC5, which have previously been linked 
to colorectal carcinoma in humans [126-128]. We confirmed using qRT-PCR analysis an 
increased expression of the top three differentially expressed genes encoding molecules 
involved in proliferation, S100A9, SNRPD1 and DBF4, identified in our microarray 
(Figure 4-4C).  
 
To further investigate the mechanism of unchecked cellular proliferation when 
AIM2 was absent, we examined activities of the phosphatidylinositol 3-Kinase–AKT 
pathway, which has a major role in cell proliferation and survival and in development of 
cancer [129]. We found increased phosphorylation of AKT at Ser473 in Aim2–/– mice 
compared with WT mice 14 days after injection of AOM (Figure 4-4D), indicating 
activation of the AKT pathway. Phosphorylation of AKT at Ser473 was similar between 
WT and Aim2–/– mice 80 days after injection of AOM (Figure 4-4D). The 
phosphatidylinositol 3-Kinase-AKT pathway is negatively regulated by the tumor 
suppressor PTEN [130]. Phosphorylation of PTEN at S380, T382, and T383 maintains 
PTEN in a relatively inactive state [131]. Indeed, we saw increased phosphorylation of 
PTEN at S380, T382, and T383 in Aim2–/– mice compared with WT mice 14 days after 
injection of AOM (Figure 4-4D). Increased AKT activation and transcription of genes 
involved in cell proliferation could explain increased proliferation in the colon of mice 
lacking AIM2 following damage induced by AOM. Consistent with increased AKT 
activation, we found an elevated level of the transcription factor and proto-oncogene c-  
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Figure 4-4. AIM2 suppresses overt proliferation. 
(A) Quantification of the number of BrdU+ cells in each crypt of WT (day 8, n = 3; day 
14, n = 5) and Aim2–/– (day 8, n = 4; day 14, n = 5) mice. Quantification of the number of 
Ki67+ in each crypt of WT (day 0, n = 4; day 14, n = 4) and Aim2–/– (day 0, n = 3; day 14, 
n = 4) mice. (B) Microarray analysis of genes encoding molecules involved in 
proliferation with significantly higher or lower expression in Aim2–/– mice 14 days after 
injection of AOM compared with their WT counterparts. (C) Real-time qRT-PCR 
analysis of genes encoding S100A9, SNRPD1, and DBF4 in WT and Aim2–/– mice 14 
days after injection of AOM. (D and E) Immunoblot analysis of phosphorylated and total 
AKT and phosphorylated and total PTEN (D) or c-Myc, HIF1-a and GAPDH (loading 
control; E) from colon tissues. (F) Real-time qRT-PCR analysis of the gene encoding c-
Myc in colon tissues of mice 14 days after injection of AOM. (G and H) Immunoblot 
analysis of caspase-3 (G) and -7 activation (H) in colon tissues of mice 8 days after 
injection of AOM. At least 20 crypts were counted in each animal (A). *p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001; NS, no statistical significance (two-tailed t test [A, 
C, and F]). Data represent one experiment with two biological replicates per genotype (B) 
or from one experiment representative of two independent experiments (A, C, and D–H) 
(mean and SEM in A, C, and F).  
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Myc in Aim2–/– mice compared with WT mice 14 and 80 days after injection of AOM 
(Figure 4-4E). Expression of the transcription factor HIF1-α, however, was similar 
between WT and Aim2–/– mice (Figure 4-4E). We further confirmed by qRT-PCR 
analysis an increased expression of the gene encoding c-Myc (Figure 4-4F). In addition, 
increased intestinal cell proliferation was linked to reduced apoptosis because the levels 
of caspase-3 and caspase-7 activation in the colon of Aim2–/– mice decreased compared 
with that in WT mice (Figure 4-4G–H). To examine possible intrinsic defects in the 
mucus layer in mice lacking AIM2, we analyzed the thickness of the mucus layer and the 
expression of genes encoding mucin, MUC2, MUC3 and MUC4, in WT and Aim2–/– 
mice. We found that the thickness of the mucus layer lining the large intestine and the 
expression levels of genes encoding MUC2, MUC3 and MUC4 were similar in WT and 
Aim2–/– mice (Figure 4-5A–B). In addition, we quantified the number of goblet cells and 
observed similar numbers of these cells in the crypts of WT and Aim2–/– mice        
(Figure 4-5C). 
 
 
AIM2 Controls Expansion of Intestinal Stem Cells 
 
We and others have previously identified that intestinal stem cells as the “cell-of-
origin” of intestinal cancer [77, 132]. We hypothesized that the dramatic increase in cell 
proliferation and tumor formation in Aim2–/– mice was caused by a population of 
intestinal stem cells which is susceptible to oncogenic insults. To investigate this, we 
cultivated and measured the growth rate of stem cells harvested from the colonic epithelia 
of untreated WT and Aim2–/– mice. Remarkably, colonic epithelial stem cells harvested 
from Aim2–/– mice consistently formed more organoids over five days compared with 
those harvested from WT mice (Figure 4-6). In addition, we measured the diameters of 
these organoids and found a greater proportion of organoids originated from Aim2–/– mice 
with a larger size compared with those isolated from WT mice (Figure 4-6). These data 
indicated that stem cells derived from the colon of Aim2–/– mice exhibited an increased 
capacity to proliferate.  
 
We and others have previously demonstrated that stem cells or progenitor cells in 
the small intestine of mice are highly susceptible to tumorigenesis induced by aberrant 
activating β-catenin mutations [77, 133]. These cells are marked by Prom1 (CD133), a 
marker of cancer stem cells in human intestinal tumors that arise as a result of aberrant 
Wnt signaling [134, 135]. To investigate the role of AIM2 in this pathway, we used the 
Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen mouse strain to investigate 
proliferation of Prom1+ cells following aberrant Wnt signaling [77]. The Prom1C-L/+ 
mouse strain contains an inducible Cre and a nuclear LacZ reporter allele knocked into 
the Prom1 locus, which allowed us to detect cells expressing Prom1 using β-
galactosidase staining. This mouse strain also encodes a Cre-dependent RosaZsGreen 
reporter allele for use in lineage tracing, which is expressed irreversibly in Prom1+ cells 
when CreERT2 is induced from the Prom1C-L/+ locus following tamoxifen treatment. 
Further, the Wnt signaling pathway is aberrant in this mouse strain owing to the presence 
of a Cre-dependent mutant allele of β-catenin (Ctnnb1lox(ex3)). To determine whether 
colon cells from mice lacking AIM2 exhibited increased tumor susceptibility to Wnt 
signaling, we crossed Aim2–/– mice to Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsGreen mice.   
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Figure 4-5. Intact mucus layer in WT and Aim2–/– mice. 
(A) Area of the mucus layer was measured from 5–7 different sections of the same mouse 
using ImageJ (n = 3 mice). (B) Relative expression of genes encoding MUC2, MUC3, 
and MUC4 in untreated WT and Aim2–/–  mice or in WT and Aim2–/– mice 14 days after 
injection of AOM. (C) The number of goblet cells was quantified in each crypt (50 crypts 
per mouse) in the colon of WT and Aim2/ mice stained with PAS and Alcian blue. Two 
tailed t test (A–C). NS, not statistically significant. Data represent one experiment (mean 
and SEM). 
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Figure 4-6. AIM2 controls proliferation of intestinal progenitor stem cells. 
Formation of organoids derived from colonic stem cells harvested from untreated WT 
and Aim2–/– mice. Quantification of the number (top right) and size of organoids (bottom 
right). Scale bars, 50 mm (left) or 200 mm (right). Data represent one of three 
independent experiments.  
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We used β-galactosidase staining to detect nuclear LacZ expression from the Prom1 
promoter. We found that a loss of AIM2 did not alter Prom1 expression pattern in the 
large intestine and the majority of cells in the colonic crypts expressed Prom1       
(Figure 4-7A). Remarkably, three weeks after induction of aberrant β-catenin activation 
by tamoxifen treatment, we observed a significant increase in the stem cell activity of 
Prom1+ cells, indicated by GFP lineage tracing using the RosaZsG allele, in the colon of 
Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice compared with Prom1C-L/+; 
Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Figure 4-8A). There was a significantly 
increased number of GFP+ cells in Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice 
relative to Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Figure 4-7B). GFP+ cells 
populated almost the entire crypts in Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice 
(Figure 4-8A). We observed very few crypts that were comprised of GFP+ cells in 
Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice (Figure 4-8A), indicating that a 
small population of Prom1+ cells could still potentially behave as stem or progenitor cells 
in the colon of Aim2+/+ mice. These findings suggested that the lack of AIM2 increased 
the stem cell activity of Prom1+ cells following aberrant Wnt activation. 
 
Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG mice succumb within six weeks of 
tamoxifen induction owing to extensive tumor formation initiated from Prom1+ stem cells 
in the small intestine (Figure 4-8B). Although we did not observe macroscopic tumors in 
the large intestine of these animals, we found an elevated number of Ki67+ cells, 
increased staining for phosphorylated AKT, total AKT and c-Myc and a small number of 
abnormal crypts in the large intestine of Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– 
mice compared with Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ mice               
(Figure 4-7C and Figure 4-8A). We also noticed accelerated tumorigenesis, increased 
staining for phosphorylated AKT and c-Myc in the small intestine of Prom1C-L/+; 
Ctnnb1lox(ex3)/+; RosaZsG; Aim2–/– mice compared with Prom1C-L/+; Ctnnb1lox(ex3)/+; 
RosaZsG; Aim2+/+ mice (Figure 4-8B). These results validated the colitis-associated 
colorectal cancer model and suggested that AIM2 played a role in protecting tumor 
formation in the intestine. Overall, loss of AIM2 resulted in an increased stem cell 
activity in the colon following aberrant Wnt-signaling in the intestinal stem-cell niche.   
 
To further confirm a role for the epithelial compartment in AIM2-mediated 
protection against colon cancer development, we performed bone marrow transplantation 
experiments to examine the contribution of the radioresistant stromal compartment 
relative to that of the hematopoietic compartment in governing colon tumorigenesis. As 
expected, Aim2–/– mice that received Aim2–/– bone marrow were more susceptible to 
tumorigenesis compared to WT mice that received WT bone marrow (Figure 4-9A). 
After 80 days post-AOM injection, Aim2–/– mice that received WT bone marrow had 
significantly increased tumor burden compared to WT mice that received WT bone 
marrow (Figure 4-9B–C). These results provided evidence to suggest that AIM2 in the 
stromal compartment could play a role in the protection against colorectal tumorigenesis. 
WT mice that received Aim2–/– bone marrow also showed slightly increased tumor 
burden compared with WT mice that received WT bone marrow, suggesting that the bone 
marrow compartment contributed to colorectal tumorigenesis via a yet-undefined 
mechanism.  
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Figure 4-7. Loss of AIM2 increased proliferation initiated by Prom1+ cells in the 
large intestine following -catenin activation. 
 (A) b-galactosidase staining of Prom1-expressing cells indicating similar expression 
pattern in the large intestine of Prom1C-L/+; Aim2+/+ and Prom1C-L/+; Aim2–/– mice. Scale 
bar, 20 mm. (B) Quantification of the number of GFP+ cells per field in the large intestine 
of Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ and Prom1C-L/+; Ctnnb1lox(ex3)/+; 
RosaZsG; Aim2–/– mice 3 weeks post-tamoxifen (TMX) induction. Fields from 10 images 
for each genotype were quantified. (C) H&E (left) and Ki67 (right) staining of the large 
intestine of Prom1C-L/+; Ctnnb1lox(ex3)/+; RosaZsG; Aim2+/+ and Prom1C-L/+; Ctnnb1lox(ex3)/+; 
RosaZsG; Aim2–/– mice 6 weeks post-TMX induction. Arrowheads indicate abnormal 
crypts. Scale bar, 50 mm (H&E, top), 100 mm (H&E, bottom), 200 mm (Ki67). Mean 
and SEM in (B). ****p < 0.0001 (two-tailed t test [B]). 
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Figure 4-8. AIM2 controls expansion of intestinal stem cells. 
(A) Lineage tracing (left) of Prom1+ cells (green) in the large intestine 3 weeks post-
tamoxifen (TMX) induction. Blue staining indicates DAPI. Scale bar, 100 mm. Staining 
for phosphorylated AKT (p-AKT, Ser473), total AKT and c-Myc (right) in the large 
intestine 6 weeks post-TMX induction. Scale bar, 200 mm. Arrow heads indicate early 
lesions with intense staining for the respective markers. (B) H&E staining and staining 
for p-AKT (Ser473), total AKT, c-Myc, and Ki67 staining in the small intestine 6 weeks 
post-TMX induction. Scale bars, 250 mm(H&E) and 100 mm (p-AKT, total AKT, c-
Myc, and Ki67 staining).  
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Figure 4-9. The role of hematopoietic and non-hematopoietic compartments in 
AIM2-mediated protection of colorectal tumorigenesis. 
(A) Four groups of mice were generated by bone marrow transplantation: (1) WT → WT, 
n = 9; (2) Aim2–/– → WT, n = 9; (3) WT → Aim2–/–, n = 7; (4) Aim2–/– → Aim2–/–, n = 8. 6 
weeks following bone marrow transplantation, mice were treated with AOM followed by 
DSS, and colon tumors were counted 80 days after injection of AOM. The numbers of 
tumors in the colon and percentages of tumors of less than 2 mm or 2–4 mm in diameter 
were quantified. (B) Representative images of colon tumors. (C) Representative H&E 
images of colon tumors. Magnification: 20. Data represent one experiment (mean and 
SEM). *p < 0.05; **p < 0.01; ***p < 0.001. One-way ANOVA (A). 
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AIM2 Protects Colorectal Tumorigenesis by Modulating the Gut Microbiota 
 
Intestinal cell proliferation and the development and progression of colorectal 
cancer is regulated by the composition of gut microbiota. Studies have reported that the 
NOD-like receptor protein NLRP6 modulates the microbial ecology and protects against 
colon tumor development [136, 137]. To assess whether the gut microbiota plays a role in 
the increased tumorigenic susceptibility of Aim2–/– mice, we performed 16S rRNA gene 
sequencing analysis of the gut microbiota derived from stool samples of separately 
housed WT and Aim2–/– mice. Our 16S rRNA gene sequencing analyses revealed a 
markedly distinct intestinal microbial landscape in separately housed WT and Aim2–/– 
mice (Figure 4-10A–B). Relative to WT mice, Aim2–/– mice harbored increased levels of 
Akkermansia muciniphila, Anaeroplasma, and decreased levels of Anaerostipes, 
Bifidobacterium, Flexispira, Prevotella and Paraprevotella species (Figure 4-10A). Of 
these, previous reports have linked an increase in Akkermansia and a decrease in 
Prevotellaceae with the development of colonic tumorigenesis [138]. Interestingly, co-
housing equilibrated the relative abundance of Anaerostipes, Flexispira, Prevotella, and 
Paraprevotella in WT and Aim2–/– mice (Figure 4-10A–B).  
 
We took advantage of the transmissible nature of the gut microbiota to investigate 
whether susceptibility to colorectal tumorigenesis could be reduced in Aim2–/– mice by 
co-housing them with WT mice. We found a striking reduction in the number and 
incidence of colon tumors in co-housed Aim2–/– mice compared with separately housed 
Aim2–/– mice (Figure 4-10C–D). Intriguingly, WT mice co-housed with Aim2–/– mice 
responded conversely and developed more tumors compared with their separately housed 
controls (Figure 4-10C–D). Co-housed Aim2–/– mice were still more susceptible to 
tumorigenesis compared with co-housed WT mice (Figure 4-10C–D), supporting the 
concept that both genetic and environmental factors contributed to the development of 
cancer. 
 
 
Discussion 
 
Members of the pattern-recognition receptor family are central players in the 
regulation of infectious, inflammatory and metabolic diseases. Our laboratory and others 
have previously shown that the innate immune receptors NLRP3, NLRP6, NLRP12, 
NLRC4, STING and NOD2 are required for the protection against colitis and colitis-
associated tumorigenesis [27-31, 139-143]. However, the role of AIM2-like receptors, 
including AIM2 and IFI16 or p202, in regulating gastrointestinal health and disease is 
unknown.  
 
The innate immune receptor AIM2 was originally isolated from human melanoma 
cells [37]. AIM2 directly binds dsDNA and initiates the recruitment of ASC and caspase-
1 to assemble a multi-protein inflammasome complex. Whether AIM2 can operate 
independently of inflammasomes in the cell is unclear. Here, we identified an unexpected 
function for AIM2 that departs from its known role in inflammasome signaling. Certain 
members of the NLR family, including NLRP6 and NLRP12, have also been shown to   
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Figure 4-10. Reciprocal exchange of gut microbiota reduces susceptibility of Aim2–
/– mice to colon cancer. 
(A) Bacterial species from feces that had the greatest difference in abundance between 
single housed WT and Aim2–/– mice and their relative abundance in co-housed WT and 
Aim2–/– mice, based on analysis of the 16S rRNA gene, are shown in a heatmap in 
alphabetical order. (B) Principal component analysis of (A). (C) The total number of 
tumors observed in the colon of separately housed and co-housed mice 80 days after 
injection of AOM. (D) Representative images of colons in (C). Data represent one 
experiment (A and B) or pooled from two independent experiments (C and D) (mean and 
SEM in [C]). *p < 0.05; ****p < 0.0001. One-way ANOVA (C).   
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exert inflammasome-dependent and inflammasome-independent functions in health and 
disease [144]. 
 
The mechanism driving AIM2-dependent protection against tumorigenesis is the 
ability of AIM2 to tightly suppress overt cellular proliferation of intestinal epithelial 
cells. Whether AIM2 directly interacts and prevents phosphorylation of the kinase AKT 
is unclear. Unlike the role for NLRP6 in targeting goblet cell mucin secretion [145], 
AIM2 specifically controlled expansion and proliferation of intestinal stem cells. The 
larger population of cells derived from Prom1+ cells lining the intestinal crypt in mice 
lacking AIM2 following aberrant induction of β-catenin indicated that these cells might 
be highly proliferative and less well-differentiated. In vitro studies have shown that 
ectopic expression of AIM2 can be used to promote cell cycle arrest and inhibition of cell 
proliferation [146]. These findings, together, highlight the dynamic roles of AIM2 in 
regulating cell functions during cell growth and tumorigenesis.  
 
In mice exposed to AOM-DSS, the expression of AIM2 was down-regulated as 
early as 14 days, suggesting that robust AIM2 expression was critical for preventing early 
tumorigenic events. The levels of AIM2 expression in tumor tissues of patients have been 
shown to greatly influence the outcome of the disease. Patients who have tumor cells that 
completely lacked AIM2 expression have a more than 3-fold higher mortality rate than 
patients whose tumor cells retained some AIM2 expression [26]. The precise molecular 
signal that triggers down-regulation of AIM2 expression during colorectal tumorigenesis 
is unknown and therapeutic strategies aimed at increasing colonic AIM2 expression may 
help to prevent overt tumorigenesis in susceptible individuals. 
 
Of particular clinical relevance is the observation that defective AIM2 function 
leading to tumorigenesis can be partially prevented by a transmissible gut microbiota in 
cohoused mice. This finding indicates that engraftment of healthy donor gut microbiota 
to patients suffering chronic intestinal inflammation could reduce the risk of developing 
colorectal cancer. The microbiota plays a central role in modulating cell proliferation in 
the intestine. Gut–associated Lactobacillus murinus enhances cell proliferation in the 
mouse intestine [147]. Furthermore, gut microbiota has the capacity to induce IL-17C 
production in intestinal epithelial cells via a MyD88-dependent pathway, which leads to 
increased expression of the prosurvival proteins Bcl2 and Bcl-xL to drive colorectal 
tumorigenesis [148]. Carbohydrate-derived metabolites generate by gut microbiota has 
also been shown to enhance colon epithelial cell proliferation in an ApcMin/+ mouse model 
lacking the gene encoding the DNA mismatch repair protein MutS homolog 2 (MSH2) 
[149]. 
 
During barrier damage, it is possible that DNA from microbial species that have 
invaded intestinal cells or DNA from dying host cells could be sensed by AIM2 in 
intestinal cells. It is tempting to hypothesize that instead of contributing to the 
inflammatory response further by inducing activation of the inflammasome, AIM2 
responds by dampening cellular proliferation in the intestine. How AIM2 might be 
sensing different environmental cues in the cytoplasm to direct context-specific cellular 
processes is an exciting question for future investigation. In conclusion, our findings 
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demonstrated a requirement for AIM2 in the protection against colorectal cancer. 
Therapeutic modulation of AIM2 expression and gut microbiota could play a central role 
in reducing the risk of developing colorectal cancer. 
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CHAPTER 5.    DETRIMENTAL TYPE I INTERFERON SIGNALING 
DOMINATES PROTECTIVE AIM2 INFLAMMASOME RESPONSES DURING 
FRANCISELLA NOVICIDA INFECTION 
 
 
Introduction 
 
Innate immune sensors mediate the recognition of PAMPs and DAMPs and are 
central regulators of host defense against microbial infections. Upon activation, immune 
sensors induce the production of inflammatory cytokines and interferons. Certain innate 
immune cytoplasmic sensors have a unique ability to form a caspase-1-activating multi-
protein complex termed the inflammasome. These sensors include members of the 
nucleotidebinding oligomerization domain (NOD), leucine-rich repeat (LRR)-containing 
protein family members, AIM2 and pyrin [150]. Of these, AIM2 binds directly to dsDNA 
and assembles the inflammasome to mediate the release of interleukin IL-1β and IL-18 
and the induction of pyroptosis. AIM2 orchestrates protective inflammasome-dependent 
responses against microbial infection in vivo, including infection by the Gram-negative 
bacterial pathogen F. novicida [150]. 
 
Components of the type I IFN signaling pathway are essential for the activation of 
AIM2 inflammasome during infection by F. novicida and L. monocytogenes [41-45, 151, 
152]. During F. novicida infection, the DNA sensor, cGAS, and its adaptor, STING, 
mediate the production of type I IFNs, which in turn drive expression of effector proteins 
of cell-autonomous immunity leading to bacteriolysis and release of bacterial DNA for 
recognition by AIM2 [150]. 
 
Type I IFN signaling during bacterial infection in vivo can be beneficial or 
detrimental depending on the pathogen [153]. Whereas type I IFN signaling is protective 
in mice infected with Streptococcus pneumoniae, or Streptococcus pyogenes, it is 
detrimental in case of F. novicida or L. monocytogenes [50]. The requirement for type I 
IFN signaling to activate the AIM2 inflammasome in macrophages is counterintuitive to 
the observation that, type I IFN signaling is detrimental during in vivo infection with F. 
novicida while the AIM2 inflammasome is protective. How the interplay between the 
opposing effects of these signaling pathways determines the final outcome during F. 
novicida infection has remained unclear. Here, we showed that the detrimental effects of 
type I IFN signaling overrides protective AIM2 inflammasome responses.  
 
  
                                                 
 Adapted with open access permission. Zhu, Q., Man S.M., Karki R., Malireddi R.K., 
Kanneganti, T.D. (2018). Detrimental type I Interferon signaling dominates protective 
AIM2 Inflammasome responses during Francisella novicida Infection. Cell Reports. 22, 
3168-3174. 
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Results and Discussion 
 
 
IFNAR Signaling Enhances Susceptibility to Infection by F. novicida 
 
A recent study has demonstrated non-redundant functions for type I IFN receptor 
subunits IFNAR1 and IFNAR2 independently of one another [154]. To directly compare 
the effects of IFNAR1 and IFNAR2 during F. novicida infection, we infected WT mice 
and mice lacking IFNAR1 (Ifnar1–/–) or IFNAR2 (Ifnar2–/–) with F. novicida and 
monitored their survival. Whereas 65% of the infected WT mice died within 14 days, 
only 13% of the Ifnar1–/– mice and 11% of the Ifnar2–/– mice succumbed to infection 
(Figure 5-1A), suggesting that signaling by both IFNAR1 and IFNAR2 contribute to 
increased susceptibility to infection by F. novicida. The resistance to F. novicida 
infection in Ifnar1–/– mice is consistent with the observations of a previous study [155]. 
Furthermore, only 8% of mice lacking the transcription factor IRF9 (Irf9–/–), a component 
of ISGF3 transducing type I IFN signaling, succumbed to infection by F. novicida over 
14 days, essentially phenocopying Ifnar1–/– and Ifnar2–/– mice (Figure 5-1A). IRFs are 
central components regulating type I IFN production in response to diverse pathogens. 
Indeed, we found that Irf7–/– and Irf3–/–Irf7–/– mice were resistant to the infection   
(Figure 5-1B). However, mice lacking IRF5, an IRF not critical for IFN production, 
(Irf5–/–) were as susceptible as WT mice (Figure 5-1B). We also observed increased 
resistance in Stinggt/gt mice (Figure 5-1B). Consistent with these results, we found 
significantly lower bacterial burdens in the liver and spleen of Stinggt/gt mice, Irf7–/– mice, 
and Irf9–/– mice 3 days after infection compared with WT mice (Figure 5-1C). Together, 
these results suggest that the effector responses mediated by type I IFN signaling enhance 
susceptibility to F. novicida infection in vivo. 
 
 
The Detrimental Effects of Type I IFN Signaling Dominate the Protective Effects of 
AIM2 during F. novicida Infection in vivo 
 
To directly assess the relative contribution of IFNs and AIM2 in host defense 
during F. novicida infection, we compared mice lacking components of the type I IFN 
signaling pathway, such as IFNAR2, with mice lacking AIM2. Whereas Ifnar2–/– mice 
were resistant to infection by F. novicida, with only 19% of the mice dying, all Aim2–/– 
mice succumbed to infection within 6 days (Figure 5-2A). The disparate roles of type I 
IFN signaling and AIM2 during F. novicida infection in vivo suggest a more complex 
functional relationship between these two pathways.  
 
To formally investigate the cumulative effects of type I IFN signaling and AIM2 
during F. novicida infection, we bred Ifnar2–/– mice and Aim2–/– mice to generate mice 
lacking both IFNAR2 and AIM2 (Ifnar2–/–Aim2–/–). Ifnar2–/–Aim2–/– mice had similar 
numbers of neutrophils, macrophages, dendritic cells, CD8+ T cells and B cells in the 
spleen, T cells in the thymus, and neutrophils, monocytes and B cells in the bone marrow 
compared with WT mice (Figure 5-3A–C). We infected Ifnar2–/–Aim2–/– mice with F. 
novicida and monitored their survival. Interesting, Ifnar2–/–Aim2–/– mice were resistant to   
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Figure 5-1. Mice lacking IFNAR1 or IFNAR2 are resistant to F. novicida. 
(A) Survival of WT, Ifnar1–/–, Ifnar2–/–, and Irf9–/– mice infected with F. novicida. (B) 
Survival of WT, Irf7–/–, Irf3–/–Irf7–/–, Irf5–/– and Stinggt/gt mice infected with F. novicida. 
(C) Bacterial burdens in the liver and spleen of WT, Stinggt/gt, Irf7/, and Irf9–/– mice 3 
days after infection with F. novicida. NS, not significant; **p < 0.01, ***p < 0.001, 
****p < 0.0001; log-rank test (A and B) or one-way ANOVA with Dunnett’s multiple-
comparisons test (C). Data are pooled from three (C) or four (A and B) independent 
experiments (mean and SEM in C). 
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Figure 5-2. Detrimental role of type I IFN signaling is dominant over AIM2 
inflammasome responses during F. novicida infection. 
(A) Survival of WT, Ifnar2–/–, Aim2–/–, and Ifnar2–/–Aim2–/– mice infected with F. 
novicida. (B) Bacterial burdens in the liver and spleen of WT, Ifnar2–/–, Aim2–/–, and 
Ifnar2–/–Aim2–/– mice 3 days after F. novicida infection. (C) Concentration of IL-18 in the 
sera of WT, Ifnar2–/–, Aim2–/–, and Ifnar2–/–Aim2–/– mice 1 day after infection. (D) 
Immunoblot analysis of pro-caspase-1 (Pro-Casp-1) and the caspase-1 subunit p20 (Casp-
1p20) in unprimed WT or mutant BMDMs left uninfected or untreated (Med, medium 
alone) or assessed 20 hours after infection with F. novicida (MOI, 100; top), 5 hours after 
transfection with poly(dA:dT) (middle), or 10 hours after infection with MCMV 
(bottom). (E) Release of IL-1b (top) or IL-18 (middle) and death (bottom) of unprimed 
BMDMs after treatment, as in (D). NS, not significant; *p < 0.05; **p < 0.01, ***p < 
0.001, ****p < 0.0001; long-rank test (A) or one-way ANOVA with Dunnett’s multiple 
comparisons test (B, C, and E). Data are pooled from three (B) or four (A and C) 
independent experiments or are from one experiment representative of two independent 
experiments (D and E) (mean and SEM in B, C, and E). 
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Figure 5-3. Characterization of Ifnar2−/−Aim2−/− mice.  
(A) Total number of neutrophils, macrophages, DCs, CD4+ T cells, CD8+ T cells, and B 
cells in the spleen of WT mice and Ifnar2−/−Aim2−/− mice. (B) Total number of CD4+ T 
cells and CD8+ T cells in the thymus of WT mice and Ifnar2−/−Aim2−/− mice. (C) Total 
number of neutrophils, monocytes, and B cells in the bone marrow of WT mice and 
Ifnar2−/−Aim2−/− mice. NS, not statically significant; *P<0.05 (two-tailed t test [A–C]). 
Data are pooled from two independent experiments (A–C; mean and SEM in A–C). 
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the infection similar to Ifnar2–/– mice, with only 19% of the mice dying of infection over 
12 days compared with 100% in Aim2–/– mice (Figure 5-2A). Consistent with the 
reduction in mortality, both Ifnar2–/–Aim2–/– and Ifnar2–/– mice had significantly lower 
bacterial burdens in the liver and spleen 3 days after infection compared with WT mice, 
while Aim2–/– mice were more susceptible to infection and had more bacterial burden 
(Figure 5-2B). These results demonstrate that type I IFN signaling is dominant over 
AIM2 inflammasome during F. novicida infection in vivo. Since both IFNAR1 and 
IFNAR2 are required for mediating detrimental type I IFN signaling, it is likely that 
Ifnar1–/–Aim2–/– mice are also resistant to the infection phenocopying Ifnar2–/–Aim2–/– 
mice. Increased number of splenic CD4+ T cells in naïve Ifnar2–/–Aim2–/– mice is unlikely 
to contribute to the susceptibility (Figure 5-3A), as bacterial burden in Ifnar2–/–Aim2–/– 
mice was significantly lower than WT mice 3 days after infection when T cell responses 
barely occurred.  
 
We next investigated whether type I IFN signaling was required for AIM2 
inflammasome-induced IL-18 production in vivo during F. novicida infection. Reduced 
levels of IL-18 were observed in the sera of Aim2–/– and Ifnar2–/–Aim2–/– mice confirming 
AIM2-dependent IL-18 production in the infected mice (Figure 5-2C). Notably, Ifnar2–/– 
mice retained the ability to produce IL-18 after the infection indicating inflammasome 
activation independently of type I IFNs in vivo (Figure 5-2C). The comparable level of 
resistance to F. novicida infection in Ifnar2–/– mice and Ifnar2–/–Aim2–/– mice suggest that 
the dominance of IFNAR signaling-mediated responses over AIM2 is independent of IL-
18.  
 
As demonstrated previously [44], Ifnar2–/– BMDMs had an impaired ability to 
activate caspase-1, trigger release of IL-1β and IL-18, and induce cell death in response 
to F. novicida compared to the WT BMDMs (Figure 5-2D–E). Aim2–/– or Ifnar2–/–Aim2–
/– BMDMs infected with F. novicida also failed to activate inflammasome responses, 
confirming specificity of F. novicida infection to the AIM2 inflammasome            
(Figure 5-2D–E). Inflammasome responses occurred normally in Ifnar2–/– cells after 
poly(dA:dT) transfection or MCMV infection (Figure 5-2D–E). Consistent with previous 
reports [44, 47], transfection of poly(dA:dT) did not induce IL-1β release in WT BMDMs 
(Figure 5-2E), possibly due to an inability of poly(dA:dT) transfection in mediating IL-
1β expression. Collectively, these results demonstrate that unlike in macrophages, AIM2 
inflammasome activation in vivo is retained even in the absence of type I IFN signaling.  
 
 
Inflammatory Cytokine Production Is Intact in the Absence of Type I IFN Signaling 
 
Previous studies showed that type I IFNs suppress production of pro-
inflammatory cytokines to prevent inflammation-associated damage and lethality during 
S. pneumonia infection [156]. To identify whether the levels of pro-inflammatory 
cytokines are differentially regulated by type I IFN signaling during infection by F. 
novicida, we analyzed a range of cytokines and chemokines 1 day after F. novicida 
infection, when WT, Ifnar2–/–, and Ifnar2–/–Aim2–/– mice had similar bacterial burden 
(Figure 5-4A). Levels of the pro-inflammatory cytokines GM-CSF, TNF, IL-6, MIP1-α, 
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IL-17, IL-12 and IFNγ and the anti-inflammatory cytokine IL-10 in the liver were 
comparable between WT, Ifnar2–/–, and Ifnar2–/–Aim2–/– mice (Figure 5-4B). The levels 
of these proinflammatory cytokines were also similar in the sera of WT, Ifnar2–/–, and 
Ifnar2–/–Aim2–/– mice at this time point (Figure 5-4C). We also measured levels of the 
cytokines 2 days after infection, when bacterial burdens were similar between the animals 
(Figure 5-5A). Whereas levels of TNF, IL-6, MIP1-α, IFNγ and IL-10 were similar in 
the liver (Figure 5-5B), levels of GM-CSF and IL-12 were decreased in both Ifnar2–/– 
and Ifnar2–/–Aim2–/– mice and level of IL-17 was decreased in Ifnar2–/– mice          
(Figure 5-5B). Interestingly, we found similar levels of TNF, IL-6, MIP1-α and IL-10 
but increased levels IL-17 and IL-12 in the sera of Ifnar2–/– and Ifnar2–/–Aim2–/– mice 
compared with WT animals (Figure 5-5C), which is consistent with a previous study 
[155], suggesting that circulating IL-17 and IL-12 may also contribute to host defense at 
this time point. Level of IFNγ was reduced in Ifnar2–/–Aim2–/– but not Ifnar2–/– mice. This 
could be due to a lack of IL-18-induced IFNγ production in Ifnar2–/–Aim2–/– mice  
(Figure 5-5C).  
 
 
Type I IFN Signaling Controls Activation of Apoptotic Caspases and Cell Death 
 
Type I IFN signaling has been shown to exert its detrimental effects to the host 
via induction of cell death during L. monocytogenes and Brucella abortus infection [50]. 
To determine whether type I IFN signaling promotes excessive cell death during F. 
novicida infection, we measured levels of apoptotic caspase-8, -3, and -7 in liver tissues 
of WT, Ifnar2–/–, and Ifnar2–/–Aim2–/– mice. In line with our hypothesis, the levels of 
cleaved caspase-8, -3 and -7 were lower in Ifnar2–/– and Ifnar2–/–Aim2–/– mice than in WT 
mice 1 and 2 days after infection (Figure 5-6A–B). These results suggest that induction 
of apoptosis is impaired in the absence of type I IFN signaling. Levels of cleaved 
caspase-3 and -7 were similar between WT and Aim2–/– mice (Figure 5-7A). 
Additionally, Ifnar2–/– and Ifnar2–/–Aim2–/– mice showed decreased cleavage of caspase-8, 
-3 and -7 on day 3 post infection (Figure 5-6C), whereas Aim2–/– mice had higher levels 
of cleaved caspase-8, -3 and -7, possibly due to excessive liver damage caused by 
uncontrolled bacteria replication (Figure 5-6C). TUNEL staining also indicated reduced 
cell death in Ifnar2–/– and Ifnar2–/–Aim2–/– mice and enhanced cell death in Aim2–/– mice 
after the infection (Figure 5-7B). We further tested role of AIM2 in mediating apoptosis 
in vitro during F. novicida infection by measuring cleavage of apoptotic caspases. 
Cleavage of caspase-8 and -3 was increased in Aim2–/– BMDMs compared with WT cells 
after the infection (Figure 5-7C). A previous study has shown that the AIM2 
inflammasome negatively regulates type I IFNs production [157]. It is possible that 
increased levels of type I IFNs in Aim2–/– BMDMs induces activation of caspase-8 and -3. 
Interestingly, caspase-7 activation was decreased in Aim2–/– BMDMs (Figure 5-7C). 
Caspsae-7 has been reported as a substrate of caspase-1 [158]. The reduced cleavage of 
caspase-7 in Aim2–/– BMDMs could be due to impaired caspase-1 activation during the 
infection. Overall, these results suggest that Aim2−/− BMDMs have increased apoptosis 
after F. novicida infection. On the other hand, apoptosis occurred similarly in infected 
Aim2–/– mice initially but further increased at a later stage of the infection compared with   
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Figure 5-4. Type I IFN signaling does not alter production of a range of 
inflammatory cytokines during F. novicida infection. 
(A) Bacterial burdens in the liver and spleen of WT, Ifnar2–/–, and Ifnar2–/–Aim2–/– mice 1 
day after infection with F. novicida. (B and C) Concentrations of GM-CSF, TNF, IL-6, 
MIP1-α, IL-17, IL-12 (p70), IFNγ, and IL-10 in the liver (B) or serum (C) of WT, Ifnar2–
/–, and Ifnar2–/–Aim2–/– mice 1 day after infection, as in (A). NS, not significant; one-way 
ANOVA with Dunnett’s multiple-comparisons test. Data are pooled from two (B and C) 
or three (A) independent experiments (mean and SEM in A–C). 
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Figure 5-5. Inflammatory cytokine production after F. novicida infection. 
(A) Bacterial burdens in the liver and spleen of WT, Ifnar2−/−, and Ifnar2−/−Aim2−/− mice 
2 days after infection with F. novicida. (B–C) Concentrations of GM-CSF, TNF, IL-6, 
MIP1-α, IL-17, IL-12 (p70), IFNγ, and IL-10 in the liver (B) or serum (C) of WT, 
Ifnar2−/−, and Ifnar2−/−Aim2−/− mice 2 days after infection as in (A). NS, not significant; 
*P<0.05; **P<0.01, ***P<0.001, ****P<0.0001 (one-way ANOVA with Dunnett’s 
multiple-comparisons test [A–C]). Data are pooled from two independent experiments 
(A–C; mean and SEM in A–C). 
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Figure 5-6. Type I IFN signaling induces apoptotic cell death. 
(A–C) Immunoblot analysis of pro-caspase-8, cleaved caspase-8, pro-caspase-3, cleaved 
caspase-3, pro-caspase-7, cleaved caspase-7, and GAPDH in liver tissue from uninfected 
animals or WT, Ifnar2−/−, and Ifnar2−/−Aim2−/− mice 1 day (A) or 2 days (B) after F. 
novicida infection or from WT, Ifnar2−/−, Ifnar2−/−Aim2−/−, and Aim2−/− mice 3 days (C) 
after F. novicida infection. (D) Immunoblot analysis of TRAIL, DR5, and GAPDH in 
liver tissues of uninfected animals or WT, Ifnar2−/−, and Ifnar2−/−Aim2−/− mice 1 day after 
infection. The asterisk indicates a non-specific band. (E) Immunoblot analysis of pro-
caspase-8, cleaved caspase-8, pro-caspase-3, cleaved caspase-3, pro-caspase-7, cleaved 
caspase-7, and GAPDH in liver tissue from WT and Ifnar2/ mice treated with PBS or 
rTRAIL 1 day after F. novicida infection. (F) Survival of WT mice that received TRAIL 
neutralizing antibody or isotype control, Ifnar2−/− mice, and Ifnar2−/−Aim2−/− mice 
infected with F. novicida. NS, not significant; **p < 0.01; ***p < 0.001, ****p < 0.0001; 
long-rank test (F). Data are pooled from three independent experiments (F) or are from 
one experiment representative of two (B and E) or four (A, C and D) independent 
experiments. 
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Figure 5-7. Analysis of apoptotic cell death and TRAIL pathway during F. 
novicida infection. 
(A) Immunoblot analysis of cleavage of caspase-8, -3 and -7 and GAPDH in liver tissue 
from WT and Aim2−/− mice 1 day after F. novicida infection. (B) TUNEL staining of 
liver tissues from WT, Ifnar2−/−, Ifnar2−/−Aim2−/−, and Aim2−/− mice 3 days after F. 
novicida infection. Scale bar, 100 μm. (C) Immunoblot analysis of cleavage of caspase-8, 
-3 and -7 and GAPDH in unprimed WT or mutant BMDMs left uninfected or assessed 20 
hours after infection with F. novicida (MOI, 100). (D) Relative expression of genes 
encoding TRAIL and DR5 in liver tissues of uninfected animals or WT, Ifnar2−/−, and 
Ifnar2−/−Aim2−/− mice 1 day after infection. (E) Immunoblot analysis of TRAIL, DR5 and 
GAPDH in liver tissue from uninfected animals or WT and Aim2−/− mice 1 day after F. 
novicida infection. The asterisk indicates a non-specific band. (F) Bacterial burdens in the 
liver and spleen of WT mice that received TRAIL-neutralizing antibody or isotype 
control and Ifnar2−/−Aim2−/− mice 3 days after infection with F. novicida. (G) 
Immunoblot analysis of cleavage of caspase-8, -3 and -7 and GAPDH in liver tissue of 
WT mice that received TRAIL-neutralizing antibody or isotype control and 
Ifnar2−/−Aim2−/− mice after F. novicida infection. NS, not significant; ****P<0.0001 
(one-way ANOVA with Dunnett’s multiple-comparisons test [D and F]). Data are pooled 
from two experiments (D) or from one experiment representative of two (A, C and E) 
independent experiments or from one experiment (B, F and G; mean and SEM in D and 
F).  
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WT mice. This could be explained by the cell-type specific differences in AIM2 function 
between BMDMs and liver where the majority of cells are hepatocytes. Similar to the 
liver tissues, BMDMs from Ifnar2–/– and Ifnar2–/–Aim2–/– mice had reduced levels of 
cleaved caspase-8, -3 and -7 compared with WT cells following F. novicida infection 
(Figure 5-7C), indicating a potential role for type I IFN signaling in activating apoptotic 
caspases in vitro. The defective caspase-1 activation in Ifnar2–/– and Ifnar2–/–Aim2–/– 
BMDMs may lead to impaired caspase-7 cleavage in these cells.  
 
TRAIL is upregulated by type I IFNs and was shown to mediate type I IFN 
signaling-induced cell death during viral and bacterial infections [50]. TRAIL binds to its 
receptor DR5 and triggers apoptosis by driving caspase-8-mediated caspase-3 and -7 
activation. We therefore hypothesize that type I IFN signaling may promote cell death 
through TRAIL pathway. We measured expression levels of TRAIL and DR5 in the liver 
and found that expression of TRAIL was upregulated in the liver of WT mice 1 day after 
infection; however, the induction was abrogated in Ifnar2–/– and Ifnar2–/–Aim2–/– mice 
(Figure 5-6D, Figure 5-7D). DR5 was similarly induced between the animals       
(Figure 5-6D, Figure 5-7D). Interestingly, the level of TRAIL was slightly reduced in 
Aim2–/– mice after the infection, while the level of DR5 was similar (Figure 5-7E). IFNγ 
can induce TRAIL expression in addition to type I IFNs (Park et al., 2004). Infected 
Aim2–/– mice may exhibit reduced IFNγ production (Pierini et al., 2013) which in turn 
leads to a modest reduction in TRAIL. However, the reduction was not significant 
enough to reduce apoptosis in Aim2–/– mice, suggesting that other mechanisms such as 
Fas (CD95/APO-1) signaling may co-exist to promote marginal cell death. Furthermore, 
treatment of rTRAIL increased cleavage of caspase-8, -3 and -7 in Ifnar2–/– mice 
compared with PBS-treated Ifnar2–/– mice after the infection (Figure 5-6E), indicating 
that type I IFN signaling induces TRAIL-mediated apoptosis during F. novicida 
infection. To further confirm that type I IFN signaling exacerbates F. novicida infection 
via the TRAIL pathway, we treated WT mice with TRAIL-neutralizing antibody or 
isotype control and infected and infected these mice along with Ifnar2–/– and Ifnar2–/–
Aim2–/– mice with F. novicida. A higher dose of F. novicida was used in these 
experiments so that any protective effects rendered by TRAIL neutralization would be 
more prominent. Although 90% of WT mice that received isotype control died, only 60% 
of WT mice that received TRAIL-neutralizing antibody succumbed to infection over 14 
days (Figure 5-6F). Neutralization of TRAIL also appeared to decrease bacterial burdens 
in the liver and spleen 3 days post infection (Figure 5-7F), demonstrating a detrimental 
role for TRAIL pathway during F. novicida infection in vivo. Moreover, WT mice that 
received TRAIL-neutralizing antibody had reduced levels of cleaved caspase-8, -3 and -7 
compared with the control animals after the infection (Figure 5-7G), further confirming 
that TRAIL pathway leads to activation of apoptotic caspases during F. novicida 
infection.  
 
In this study, we demonstrate type I IFN-induced apoptosis in the liver following 
F. novicida infection and the pathogenic effects of type I IFN signaling dominate the 
protective AIM2 responses (Figure 5-8). Type I IFN signaling has been shown to 
enhance susceptibility to L. monocytogenes and B. abortus infection by promoting cell 
death in the spleen with an ability to induce Trail expression [159-162]. Moreover,     
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Figure 5-8. Opposing roles for type I IFNs signaling and AIM2 inflammasome 
responses during Francisella novicida infection in vivo.  
cGAS-STING pathway induces production of type I IFNs in response to Francisella 
novicida infection in vivo, leading to induction of TRAIL and TRAIL-dependent extrinsic 
apoptotic cell death. On the other hand, AIM2 inflammasome is activated potentially via 
bacteriolysis of Francisella by GBPs and IRGB10. The detrimental type I IFN signaling 
overrides protective AIM2 inflammasome responses.   
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Trail–/–- mice have decreased bacterial burdens in the liver and spleen and reduced splenic 
cell death after L. monocytogenes infection [163]. Increased apoptosis during F. novicida 
infection could lead to loss of hepatocytes, which have crucial roles in controlling 
infection [164]. An expansion of IL-17-producing γδ T cells is attributed to the 
phenotype of Ifnar1–/– mice in a previous study [155]. Since reduced activation of 
apoptotic caspases in Ifnar2–/– and Ifnar2–/–Aim2–/– mice occurred as early as day 1 post 
infection, preceding the elevation of IL-17 and IL-12 in the serum, it is intriguing to 
hypothesize that certain immune cells such as γδ T cells may exhibit dampened cell death 
in the absence of type I IFN signaling, leading to an increased production of circulating 
IL-17 and IL-12. Type I IFN signaling is necessary for activating AIM2 inflammasome in 
BMDMs infected with F. novicida via regulation of IRF1 and IRF1-mediated induction 
of GBPs and IRGB10 [150]. However, in contrast to mice lacking type I IFN signaling, 
mice lacking IRF1, GBPs or IRGB10 are susceptible to the infection due to impaired 
AIM2 inflammasome responses [44, 47]. Since activation of AIM2 inflammasome is 
IFNAR-independent in vivo, expression of IRF1, GBPs and IRGB10 might be intact in 
mice lacking type I IFN signaling because of the redundant induction by other types of 
IFNs. Consistent with this, priming Ifnar1–/– BMDMs with IFNγ bypasses the 
requirement for type I IFN signaling in the activation of the AIM2 inflammasome 
induced by F. novicida infection [45]. Overall, our work highlights the dominant role of 
type I IFN signaling, which exacerbates F. novicida infection in vivo, as opposed to the 
protective role of the AIM2 inflammasome. 
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CHAPTER 6.    GASDERMIN D MEDIATES PROTECTION AGAINST 
FRANCISELLA NOVICIDA BY PROMOTING INFLAMMASOME 
ACTIVATION 
 
 
Introduction 
 
Inflammasomes are innate immune multiprotein complexes formed by activation 
of innate immune sensors including NOD-like receptors, AIM2 or pyrin in response to 
pathogen-associated molecular patterns or danger-associated molecular patterns [63]. 
AIM2 is a cytoplasmic sensor for dsDNA. Upon activation, AIM2 assembles the 
inflammasome complex with adaptor ASC to mediate caspase-1 activation and caspase-
1-dependent pyroptosis and release of pro-inflammatory cytokines IL-1 and IL-18 [32-
35].  
 
GSDMD was recently discovered as an executioner of pyroptotic cell death 
downstream of caspase-1 and caspase-11 [51-53]. GSDMD belongs to the gasdermin 
family of proteins and is maintained in an auto-inhibitory form under steady state. 
Inflammatory caspases including caspase-1 and -11 cleave at a link region between the 
N- and C-terminal of GSDMD, releasing the N-terminal fragment from inhibited by the 
C-terminal domain [51-53]. The N-terminal end of GSDMD binds to phosphoinositides 
located in the inner leaflet of the plasma membrane and forms pores on the membrane 
leading to cell lysis [54-58]. Recent studies have further shown that pores generated by 
GSDMD can function as channels to allow secretion of IL-1 and IL-18 independently of 
pyroptosis [59, 60].  
 
AIM2 recognizes dsDNA originated from Gram-negative bacterium Francisella, 
DNA viruses MCMV and vaccinia virus and host cells, thereby exhibiting crucial roles in 
microbial infections and autoimmune diseases [41-43, 121, 165-167]. Mice lacking 
AIM2, ASC or caspase-1 are highly susceptible to infection by F. novicida, 
demonstrating a protective role for AIM2 inflammasome during the infection [41, 43-45, 
47, 83, 168]. IL-1 and IL-18 have been further shown to mediate the beneficial effects 
of AIM2 in response to Francisella tularensis Live Vaccine Strain [61, 62]. However, the 
role of pyroptosis downstream of AIM2 inflammasome is unknown. In this study, we 
showed that mice lacking the effector molecule of pyroptotic cell death, GSDMD, are 
susceptible to F. novicida infection. We further found that although cleavage of GSDMD 
is dependent on AIM2 inflammasome, GSDMD itself is required for optimal caspase-1 
activation. Interestingly, GSDMD is also required for caspase-1 activation triggered by 
other AIM2 inflammasome stimuli including poly(dA:dT) transfection and MCMV 
infection. 
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Results  
 
 
GSDMD Is Required for Host Defense Against F. novicida Infection 
 
Mice lacking AIM2 inflammasome components such as AIM2 (Aim2–/–) or 
caspase-1 (Casp1–/–) were previously reported to be susceptible to F. novicida infection 
[41, 43-45, 47, 83, 168]. Consistent with previous findings, we found that Aim2–/– and 
Casp1–/– mice were susceptible to F. novicida infection (Figure 6-1A). Following 
assembly of the inflammasome, activated caspase-1 cleaves pro-IL-1 and pro-IL-18 into 
mature forms and mediates their release from the cell. We therefore tested the role of IL-
1 and IL-18 during F. novicida infection. Similar to Aim2–/– and Casp1–/– mice, mice 
lacking both IL-1R and IL-18 (Il1r–/–Il18–/–) were also highly susceptible and succumbed 
to death within 3 days of the infection (Figure 6-1A), highlighting a protective role for 
IL-1 and IL-18 downstream of inflammasome activation during F. novicida infection.  
 
GSDMD mediates pyroptosis downstream of AIM2 inflammasome in response to 
DNA transfection [53]. To test the role of pyroptosis during F. novicida infection, we 
infected WT mice and mice lacking GSDMD (Gsdmd–/–) with F. novicida and monitored 
the survival. While 70% of WT survived on day 14 post infection, only 10% of Gsdmd–/– 
mice survived during the course of infection (Fig. 1A). Furthermore, Gsdmd–/– mice had 
significantly increased bacterial burden in the liver and spleen 3 days after F. novicida 
infection (Figure 6-1B), further confirming a protective role for GSDMD. Pores formed 
by GSDMD have been shown to mediate secretion of IL-1 and IL-18. Indeed, we 
observed reduced level of circulating IL-18 in Gsdmd-/- mice compared to WT mice 1-day 
post infection (Figure 6-1C). 
 
 
GSDMD Is Necessary for Optimal Caspase-1 Activation by F. novicida 
 
Inflammasome activation is critical for host defense against F. novicida infection 
in vivo. To test whether inflammasome activation is affected in the absence of GSDMD, 
we generated bone marrow-derived macrophages (BMDMs) from WT, Gsdmd–/– and 
Aim2–/– mice. The population of CD11b+F4/80+ macrophage was comparable between 
WT and Gsdmd–/– BMDMs (Figure 6-2A), suggesting that there is no difference in the 
extent of macrophage differentiation. We then infected BMDMs from WT, Gsdmd–/– and 
Aim2–/– mice with F. novicida and measured cleavage of pro-caspase-1 into its active 
form (p20) following assembly of inflammasome. Interestingly, Gsdmd–/– BMDMs 
showed decreased activation of caspase-1 compared to WT cells after F. novicida 
infection (Figure 6-3A), highlighting the requirement of GSDMD for inflammasome 
activation in response to F. novicida. Caspase-1 activation was reduced in Gsdmd–/– 
BMDMs after infection with multiple MOIs of F. novicida (Figure 6-2B). In addition, 
we observed impaired IL-1 and IL-18 release in F. novicida-infected Gsdmd–/– BMDMs, 
potentially due to impaired caspase-1 activation along with defective pore formation 
(Figure 6-3B), whereas secretion of TNF was similar between the cells (Figure 6-4). 
GSDMD has been shown to mediate pyroptotic cell death upon AIM2 inflammasome   
 60 
 
 
Figure 6-1. GSDMD contributes to host defense against F. novicida infection. 
(A) Survival of WT, Gsdmd−/−, Aim2−/−, Casp1−/− and Il1r−/−Il18−/− mice infected with F. 
novicida. (B) Bacterial burden in the liver and spleen of WT and Gsdmd−/− mice 3 days 
after infection with F. novicida. (C) Concentration of IL-18 in the sera of WT and 
Gsdmd−/− 1 day after the infection. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 (log-
rank test [A] or two-tailed t test [B]). Data are pooled from two independent experiments 
(A) or from one experiment (B–C); mean and SEM in B–C). 
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Figure 6-2. GSDMD regulates caspase-1 activation and cell death after various 
doses of F. novicida infection. 
(A) Flow cytometric analysis of CD11b+F4/80+ BMDMs generated from WT and 
Gsdmd–/– mice. (B) Immunoblot analysis of pro-caspase-1 (Pro-Casp-1) and the caspase-
1 subunit p20 (Casp-1 p20) in unprimed WT or mutant BMDMs left uninfected (medium 
alone [Med]) or assessed 20 h after infection with varying MOIs (10, 50, 150 or 200) of 
F. novicida. (C) Cell death analysis by Incucyte after infection as in (B). Data are 
representative of two independent experiments (A–C; mean and SEM in C). 
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Figure 6-3. GSDMD promotes casaspse-1 activation by F. novicida. 
(A) Immunoblot analysis of pro-caspase-1 (Pro-Casp-1) and the caspase-1 subunit p20 
(Casp-1 p20) in unprimed WT or mutant BMDMs left uninfected (medium alone [Med]) 
or assessed 20 h after infection with F. novicida (MOI, 100). (B) Release of IL-18 (left) 
and IL-1β (right) in unprimed BMDMs after infection as in (A). (C and D) Cell death 
analysis by Incucyte (C) or LDH release (D) after infection as in (A). (E) Representative 
images of Sytox Green staining by Incucyte (Scale bar, 100 m) or light microscopy 
(Scale bar, 25 m) of BMDMs after infection with F. novicida (MOI, 100). Arrowheads 
indicate representative pyroptotic cells. **P<0.01, ***P<0.001, ****P<0.0001 (one-way 
ANOVA with Dunnett’s multiple comparisons test [B and D]). Data are representative of 
two (B), three (C, D and E) or six (A) independent experiments (mean and SEM in B, C 
and D). 
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Figure 6-4. TNF release is normal in the absence of GSDMD. 
Release of TNF in unprimed BMDMs assessed 20 h after infection with F. novicida 
(MOI, 100; left), 3 h transfection with poly(dA:dT) (middle), or 10 h infection with 
MCMV (right). NS, not significant (one-way ANOVA with Dunnett’s multiple 
comparisons test). Data are representative of two independent experiments (mean and 
SEM). 
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activation induced by cytoplasmic transfection of dsDNA [53]. To test the requirement of 
GSDMD in pyroptosis triggered by F. novicida infection, we first monitored the extent of 
cell death in WT, Gsdmd–/– and Aim2–/– BMDMs after F. novicida infection using Sytox 
Green staining and found that Gsdmd–/– BMDMs exhibited lower number of Sytox-Green 
positive cells than WT BMDMs over the course of the infection                              
(Figure 6-2C, Figure 6-3C, Figure 6-3E). Consistent with the Sytox green staining, 
LDH release was also decreased in Gsdmd–/– BMDMs 20 hours post infection, which 
further confirms that pyroptosis in BMDMs during F. novicida infection is dependent on 
GSDMD (Figure 6-3D–E). Interestingly, GSDMD-independent cell death was also 
observed in Gsdmd–/– BMDMs after F. novicida infection suggesting that other molecules 
may exist to mediate F. novicida-induced pyroptosis (Figure 6-2C, Figure 6-3C–E). 
 
 
GSDMD Is Necessary for Optimal Caspase-1 Activation by Other AIM2 
Inflammasome Triggers 
 
In addition to F. novicida infection, AIM2 inflammasome can also be activated by 
transfection of poly(dA:dT) or MCMV infection. We found that caspase-1 activation 
induced by transfection of dsDNA ligand, poly(dA:dT) was partially reduced in Gsdmd–/– 
BMDMs compared with WT cells (Figure 6-5A). Gsdmd–/– BMDMs exhibited 
compromised release of IL-18 but not TNF (Figure 6-5B, Figure 6-4). Consistent with 
previous studies [53, 169], cell death was completely abolished in poly(dA:dT)-
transfected Gsdmd–/– BMDMs during the early phase of stimulation (Figure 6-5C–E). 
Furthermore, MCMV-induced caspase-1 activation was dampened in Gsdmd–/– BMDMs 
compared with WT BMDMs (Figure 6-5F). Release of IL-1 and IL-18 in MCMV-
infected Gsdmd–/– BMDMs were impaired (Figure 6-5G), while TNF secretion was 
comparable between WT and Gsdmd–/– BMDMs (Figure 6-4). Altogether, these data 
demonstrate that GSDMD is necessary for optimal caspase-1 activation in response to 
AIM2 inflammasome triggers including F. novicida and MCMV infection and, to a lesser 
extent, poly(dA:dT) transfection and that GSDMD plays a critical role in mediating 
pyroptosis after AIM2 inflammasome activation.  
 
 
AIM2 Inflammasome Cleaves GSDMD during F. novicida Infection 
 
Previous studies have shown that GSDMD is cleaved downstream of 
inflammasome activation. To test if AIM2 inflammasome is able to mediate GSDMD 
cleavage following F. novicida infection, we infected cells with F. novicida and observed 
impaired cleavage of GSDMD in BMDMs lacking AIM2 (Aim2–/–) or ASC (Asc–/–) 
(Figure 6-6A), suggesting that AIM2 inflammasome is required for GSDMD cleavage. 
Type I IFN signaling is required for activating AIM2 inflammasome in macrophages 
during F. novicida infection via induction of transcriptional factor IRF1, an interferon-
stimulated gene, which leads to IRF1-mediated expression of cell-autonomous immunity 
proteins including GBP2, GBP5 and IRGB10, leading to bacteriolysis and release of 
bacterial DNA [41-45, 47, 152, 155]. To investigate the involvement of GBPs in AIM2 
mediated GSDMD cleavage, we utilized mice lacking multiple GBPs (including GBP2   
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Figure 6-5. GSDMD is necessary for optimal casaspse-1 activation by other AIM2 
inflammasome triggers. 
(A) Immunoblot analysis of pro-caspase-1 (Pro-Casp-1) and the caspase-1 subunit p20 
(Casp-1 p20) in unprimed WT or mutant BMDMs untreated (medium alone [Med]) or 
assessed 3 h after transfection with poly(dA:dT). (B) Release of IL-18 in unprimed 
BMDMs after treatment as in (A). (C and D) Cell death analysis by Incucyte (C) or LDH 
release (D) after treatment as in (A). (E) Representative images of Sytox Green staining 
by Incucyte (Scale bar, 100 m) or light microscopy (Scale bar, 25 m) of BMDMs after 
transfection with poly(dA:dT). Arrowheads indicate representative pyroptotic cells. (F) 
Immunoblot analysis of pro-caspase-1 (Pro-Casp-1) and the caspase-1 subunit p20 (Casp-
1 p20) in unprimed WT or mutant BMDMs left uninfected (medium alone [Med]) or 
assessed 10 h after infection with 10 MOI of MCMV. (G) Release of IL-18 (left) and IL-
1β (right) in unprimed BMDMs after infection as in (F). *P<0.01, **P<0.01, 
***P<0.001, ****P<0.0001 (one-way ANOVA with Dunnett’s multiple comparisons test 
[B, D and G]). Data are representative of two (B, F and G), three (C, D, E) or six (A) 
independent experiments (mean and SEM in B, C, D and G). 
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Figure 6-6. GSDMD cleavage is dependent on AIM2 inflammasome. 
(A and B) Immunoblot analysis of pro-GSDMD (GSDMD), cleaved N-terminal of 
GSDMD (GSDMD-NT) and GAPDH in unprimed WT, Aim2–/– and Asc–/– BMDMs (A) 
or WT and Gbpchr3-KO BMDMs (B) infected with F. novicida (MOI, 20). Data are 
representative of two independent experiments (A and B). 
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and 5) encoded on chromosome 3 (Gbpchr3-KO) and infected BMDMs from Gbpchr3-KO 
mice with F. novicida. We found that Gbpchr3-KO BMDMs also exhibited reduced 
cleavage of GSDMD (Figure 6-6B). Overall, these data demonstrate that although 
caspase-1 activation induced by AIM2 inflammasome triggers is largely dependent on 
GSDMD, GSDMD cleavage still requires AIM2 inflammasome. 
 
 
Discussion 
 
Pyroptosis is a lytic form of cell death that is induced by inflammasomes leading 
to release of mature IL-1 and IL-18 and other cellular components including high-
mobility group box 1 (HMGB1) and IL-1. It has not been discovered until recently that 
GSDMD induces pyroptosis by forming pores on plasma membrane after being activated 
by caspase-1 or -11 [51-53]. In this study, we demonstrated a protective role for GSDMD 
during F. novicida infection. While caspase-1 processing is intact in the absence of 
GSDMD downstream of canonical NLRP3, NLRC4 or pyrin inflammasome [52, 53], we 
observed that activation of caspase-1 is impaired in Gsdmd–/– BMDMs in response to 
AIM2 inflammasome stimuli. Given that a residual amount of caspase-1 activation was 
observed in Gsdmd–/– BMDMs infected with F. novicida, it is intriguing to hypothesize 
that during the early phase of F. novicida infection, caspase-1 is activated in a GSDMD 
independent manner. Activated caspase-1 may cleave GSDMD to allow the N-terminal to 
target F. novicida in the cytosol leading to bacteriolysis and release of bacterial DNA, 
which potentially amplifies activation of AIM2 inflammasome and further GSDMD 
cleavage at later phase of F. novicida infection in a positive feedback manner. Indeed, 
GSDMD has been shown to be associated with phosphoinositides and cardiolipin [54, 56, 
57], the latter of which is a component of F. novicida membrane as well as mitochondria 
[170]. Moreover, incubation of the N-terminal fragment of GSDMD with E. coli or 
Staphylococcus aureus in vitro leads to reduced bacterial CFU [57]. Furthermore, higher 
CFU of Listeria monocytogenes is observed in GSDMD-knocked down BMDMs [57], 
revealing a bactericidal role for GSDMD during intracellular bacterial infection [56, 57].  
 
Consistent with this hypothesis, we also observed a higher bacterial burden in 
Gsdmd–/– mice after F. novicida infection. Polymers that facilitate transfection of 
poly(dA:dT) or viral particles may be targeted by GSDMD similarly as F. novicida, 
which explains a reduction in caspase-1 activation in the absence of GSDMD in response 
to poly(dA:dT) transfection and MCMV infection. In addition to the possibility that 
GSDMD targets bacterial membrane, GSDMD-mediated pore formation on plasma 
membrane at early phase of F. novicida infection may act in a feed forward loop giving 
an un-identified secondary signal for AIM2 inflammasome activation. It is also possible 
that GSDMD binds to cardiolipin which is located at inner-membrane of mitochondria. 
Pores may form by GSDMD on mitochondria inducing mitochondria damage and release 
of mitochondria DNA or other mitochondria-associated molecules into cytosol, serving 
as a potential source for AIM2 inflammasome activation. In addition, although levels of 
cell death and release of IL-1β and IL-18 are greatly reduced in Gsdmd–/– BMDMs 
stimulated with AIM2 inflammasome triggers compared with WT cells, the levels are 
still higher than those in Aim2–/– BMDMs, suggesting that additional mechanisms may 
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mediate pyroptosis and pyroptosis-dependent IL-1β and IL-18 release downstream of 
AIM2 inflammasome activation. Consistent with our findings, GSDMD-independent cell 
death and cytokine release are also reported previously [52, 169]. It is intriguing to 
hypothesize that other members of GSDMD family such as GSDME can be activated by 
AIM2 to induce pore formation on cell membrane leading to pyroptosis [171, 172]. 
Altogether, our study highlights a critical role for GSDMD in mediating host defense 
against F. novicida infection and further underscores a requirement for GSDMD in 
promoting optimal caspase-1 activation following AIM2 inflammasome triggers. 
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CHAPTER 7.    DISTINCT REGULATORY MECHANISMS CONTROL 
PROINFLAMMATORY CYTOKINES IL-18 AND IL-1 
 
 
Introduction 
 
IL-18 and IL-1β, members of the IL-1 cytokine family, are important mediators of 
inflammatory diseases and play critical roles in infection and cancer [65-67, 173]. Unlike 
other cytokines, cellular IL-18 and IL-1β are synthesized as precursor proteins and need 
to be cleaved to generate their biologically active forms. Inflammasome, a multimeric 
protein complex, is a central regulator of this process by which bioactive IL-18 and IL-1β 
are generated. The inflammasome comprises an innate immune sensor that includes the 
NOD-like receptor, AIM2-like receptor, and pyrin; the adaptor protein ASC; and the 
cysteine protease caspase 1 [36]. Inflammasome assembly induces the activation of 
caspase-1, which mediates the proteolytic processing of pro-IL-18 and pro-IL-1β to 
generate their bioactive forms and their release from the cell [36]. 
 
IL-18 is constitutively expressed in blood monocytes and intestinal epithelial cells 
of healthy humans [68, 174]. It is also expressed in murine macrophages, dendritic cells, 
endothelial cells, intestinal epithelial cells, and keratinocytes under steady state [175-
177]. However, IL-1β is not constitutively expressed under homeostasis. IL-1β 
expression is induced in blood mononuclear cells, macrophages, and dendritic cells 
during stimulation with TLR ligands and other cytokines (e.g., TNF) [65-67]. Unlike IL-
1β, a cellular pool for IL-18 already exists before an inflammatory stimulus, and is ready 
to be activated and released by the inflammasome [64]. It must however be noted that 
LPS-mediated priming of NLRP3 is required for inflammasome activation and 
subsequent release of both IL-18 and IL-1 [178]. However, several studies suggest that 
despite being constitutively expressed, IL-18 can also be induced under certain 
circumstances. Treatment with LPS (TLR4 agonist) has been shown to upregulate the 
mRNA levels of Il18 [68, 69]. Incubation of CpG oligonucleotides (TLR9 agonist) with 
dendritic cells or infection of monocytes with the Sendai virus can also increase the 
expression of Il18 [70, 71].  
 
The mechanisms by which IL-18 and IL-1β levels are regulated by different 
inflammatory signals remain unclear. In this study, we showed that expression of IL-18 is 
induced and that the increased level is sustained during TLR4, TLR2, or TLR7 ligands 
stimulation. In contrast, IL-1β expression declines soon after reaching its peak level. The 
TLR3 and cGAS-STING pathways induced IL-18 but were modest at inducing IL-1β 
expression. Importantly, type I IFN signaling was required to upregulate IL-18 in 
response to all stimuli tested. Thus, in macrophages lacking components of type I IFN 
signaling, IL-18 was not induced by any inflammatory stimuli. Together, our findings 
                                                 
 Adapted with permission. Zhu, Q. and T.D. Kanneganti, Cutting Edge: Distinct 
Regulatory Mechanisms Control Proinflammatory Cytokines IL-18 and IL-1β. J 
Immunol, 2017. 198(11): p. 4210-4215. Copyright 2017. The American Association of 
Immunologists, Inc. 
 70 
demonstrate that IL-18 and IL-1β expression are differentially regulated. Expression of 
these inactive pro-inflammatory cytokines is an essential step for their maturation into 
bioactive forms by caspase-1 inflammasomes. Overall, our data demonstrating 
differential regulation of IL-18 and IL-1β will be fundamental to understanding several 
inflammatory disease settings. 
 
 
Results and Discussion 
 
 
IL-18 and IL-1β Are Differentially Induced in Response to Inflammatory Stimuli 
 
TLRs, one of the major types of pattern recognition receptors in the cell [179], 
induce expression of pro-inflammatory cytokines and type I IFNs in response to 
pathogen-associated molecular patterns and damage-associated molecular patterns [179]. 
We first confirmed that IL-18 was constitutively expressed in untreated WT BMDMs, 
similar to previous reports [68, 175]. Interestingly, we observed that its expression was 
upregulated by the TLR4 ligand LPS (Figure 7-1A). As expected, Il1b was not expressed 
in untreated BMDMs but was induced shortly after LPS treatment (Figure 7-1A). 
Interestingly, although gene and protein expression of IL-18 was sustained 24 hours after 
stimulation, that of IL-1β was induced initially but reduced substantially at 24 hours 
(Figure 7-1A). These results suggest that the expressions of IL-18 and IL-1β are 
differentially regulated after LPS stimulation.  
 
After binding to TLR4, LPS signals through both the MyD88 and TRIF pathways 
[179]. To determine the specific roles of MyD88 and TRIF pathways in regulating IL-18 
and IL-1β expression, we treated cells with ligands that signal through either the MyD88 
or TRIF pathway. Interestingly, Pam3CSK4, which signals through the MyD88 pathway 
downstream of TLR2 induced sustained expression of IL-18 over the treatment period in 
WT BMDMs (Figure 7-1B). On the other hand, IL-1β was upregulated 4 hours after 
treatment but diminished dramatically at later time points (Figure 7-1B). Gardiquimod 
induces the MyD88 pathway downstream of TLR7. Induction kinetics of mRNA 
expression and protein levels of IL-18 and IL-1β in WT BMDMs treated with 
gardiquimod were similar to those treated with Pam3CSK4 (Figure 7-2). Poly(I:C) is 
sensed by TLR3 to activate the TRIF pathway. Poly(I:C) treatment induced Il18 
expression in WT BMDMs. It also induced Il1b expression, although at a much lower 
fold induction than by LPS, Pam3CSK4, and gardiquimod (Figure 7-1C). These findings 
suggest that the TRIF pathway moderately induces Il1b expression, and both the MyD88 
and TRIF pathways induce Il18 expression. Taken together, our results show that IL-18 
and IL-1β can be induced by various TLR ligands. Further, during chronic TLR 
stimulation, IL-18 expression is sustained but IL-1β expression is downregulated. These 
data suggest distinct regulatory pathways that control the expression of pro-IL-18 and 
pro-IL-1β levels during chronic TLR stimulation.  
 
One of the prominent mediators induced by the TRIF pathway are type I IFNs, 
including IFNβ [179]. Poly(I:C) induced the expression of Il18 comparable to LPS   
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Figure 7-1. IL-18 and IL-1β are differentially expressed in response to 
inflammatory stimuli.  
(A–D) Real-time qPCR ana1ysis of genes encoding IL-18 and IL-1β and immunoblot 
analysis of pro-IL-18, pro-IL-1β, and β-actin (loading control) in WT BMDMs at various 
time points after LPS (A), Pam3CSK4 (B), poly(I:C) (C), or IFN-β (D) treatment. Data 
are representative of three independent experiments 
 
 
 
 
 
Figure 7-2. Kinetics of IL-18 and IL-1β expression stimulated by gardiquimod. 
(A) Real-time qPCR analysis of the genes encoding IL-18 and IL-1β and immunoblot 
analysis of pro-IL-18, pro-IL-1β and β-actin (loading control) in WT BMDMs at various 
times after treated with gardiquimod. Data are representative of three independent 
experiments. 
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stimulation, which led us to hypothesize that the induction of Il18 requires type I IFNs. 
To determine the role of type I IFNs in modulating the expressions of Il18 and Il1b, we 
treated WT BMDMs with recombinant IFNβ and measured Il18 and Il1b expression. IL-
18 mRNA and protein levels were induced after IFNβ treatment, but IL-1β mRNA and 
protein levels were only modestly induced at levels similar to those seen for Poly(I:C) 
stimulation (Figure 7-1C−D). Overall, these data suggest that treatment of type I IFNs 
upregulates IL-18 expression. 
 
 
Induction of IL-18 but Not IL-1β Is Dependent on Type I IFN Signaling 
 
To test whether type I IFN signaling was required for induction of Il18 expression 
by inflammatory stimuli, we treated WT BMDMs and cells lacking the subunit of type I 
IFN receptor IFNAR1 (Ifnar1−/−) with LPS and monitored the expression of Il18 and Il1b 
over the treatment period. LPS treatment led to upregulation of IL-18 in WT BMDMs as 
early as 4 hours after treatment. IL-18 expression further increased and was sustained 
during chronic LPS treatment (Figure 7-3A). Surprisingly, this induction of IL-18 by 
LPS was impaired in Ifnar1−/− cells (Figure 7-3A), indicating that type I IFN signaling is 
crucial to induce IL-18 during LPS treatment. In WT BMDMs, IL-1β expression 
increased 4 hours and 8 hours after treatment but diminished at later time points    
(Figure 7-3A). Unlike Il18, induction of IL-1β remained largely intact in Ifnar1−/− cells 
(Figure 7-3A). Moreover, expression of Il1b mRNA and protein was higher in Ifnar1−/− 
BMDMs than in WT BMDMs 16 hours and 24 hours after stimulation (Figure 7-3A), 
suggesting that type I IFN signaling may negatively regulate Il1b expression during 
chronic LPS stimulation.  
 
To further test whether the induction of IL-18 by stimuli that trigger only the 
MyD88 or TRIF pathway also depends on type I IFN signaling, we treated WT and 
Ifnar1−/− BMDMs with Pam3CSK4, gardiquimod, or Poly(I:C). Induction of IL-18 was 
abolished in Ifnar1−/− BMDMs compared with WT BMDM when MyD88 signaling was 
triggered by Pam3CSK4 or gardiquimod treatment (Figure 7-3B−C). However, IL-1β 
expression remained unchanged in Ifnar1−/− BMDMs after either stimulation (Fig. 2B and 
2C). Further, during treatment with Poly(I:C), which signals via the TRIF pathway, IL-18 
induction was impaired in Ifnar1−/− BMDMs compared with WT BMDMs (Figure 7-3D). 
Recognition of cytosolic DNA by the cGAS-STING pathway results in the production of 
type I IFNs [10]. We hypothesized that stimuli that induce the production of type I IFNs 
will promote IL-18 expression that is dependent on type I IFN signaling. Therefore, we 
activated the cGAS-STING pathway by transfecting double-stranded DNA, poly(dA:dT), 
or the STING ligand cGAMP in BMDMs. Expression of Il18 was increased by activation 
of the cGAS-STING pathway (Figure 7-3E−F), but that of Il1b was not robustly induced 
(Figure 7-3E−F). As expected, the induction of Il18 was lower in Ifnar1−/− BMDMs in 
response to poly(dA:dT) or cGAMP than in WT BMDMs (Figure 7-3E−F). Collectively, 
these results suggest that type I IFN signaling is critical for induction of IL-18, but not 
IL-1β after inflammatory stimulations.  
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Figure 7-3. Type I IFN signaling is essential for induction of IL-18 but not IL-1β. 
(A) Immunoblot analysis of pro-IL-18, pro-IL-1β, and β-actin (loading control) and real-
time qPCR analysis of genes encoding IL-18 and IL-1β in WT or Ifnar1−/− BMDMs at 
various time points after LPS treatment. (B–D) Immunoblot analysis of pro-IL-18, pro-
IL-1β, and β-actin (loading control) in WT or Ifnar1−/− BMDMs at various time points 
after Pam3CSK4 (B), gardiquimod (C), or poly(I:C) (D) treatment. (E and F) 
Immunoblot analysis of pro-IL-18, pro-IL-1β, and β-actin (loading control) in untreated 
WT or Ifnar1−/− BMDMs (medium alone [Med]) or BMDMs at 8 h after transfected with 
poly(dA:dT) (E) or 2’3’-cGAMP (cGAMP) (F). Data are representative of three 
independent experiments. 
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Components of Type I IFN Signaling Are Essential to Induce IL-18 
 
The type I IFN receptor is a heterodimeric complex formed by IFNAR1 and 
IFNAR2 [180]. Binding of type I IFN to IFNAR1 and IFNAR2 induces the formation of 
ISGF3 by STAT members STAT1, STAT2, and IRF9, which function as transcriptional 
factors to induce the expression various interferon-stimulated genes (ISGs) [180]. To test 
whether other components of type I IFN signaling are also required to induce IL-18, we 
first measured IL-18 and IL-1β levels in WT BMDMs and cells lacking IFNAR2, IRF9, 
or STAT1 (Ifnar2−/−, Irf9−/− and Stat1−/−, respectively) after LPS treatment. Similar to 
Ifnar1-/- BMDMs, induction of IL-18 was also impaired in Ifnar2−/−, Irf9−/−, and Stat1−/− 
BMDMs (Figure 7-4A). However, expression of Il1b mRNA and protein was not 
compromised but showed a slight increase at 16 hours and 24 hours after stimulation in 
Ifnar2−/−, Irf9−/−, and Stat1−/− BMDMs (Figure 7-4A). Moreover, pro-IL-18 was not 
upregulated in Ifnar2−/−, Irf9−/−, and Stat1−/− BMDMs treated with Pam3CSK4 or 
Poly(I:C) compared with WT BMDMs (Figure 7-4B−C). ISGF3 directly binds to 
promoters of ISGs to induce their expression, some of which include IRFs that function 
as transcriptional factors to drive the expression of additional genes [181]. To test 
whether IL-18 was induced via ISGF3 or other IRFs downstream of the type I IFN 
receptor, we stimulated Ifnar1−/−, Ifnar2−/−, Irf9−/−, and Stat1−/− BMDMs with 
recombinant IFNβ and observed that IFNβ–induced expression of Il18 was compromised 
in Ifnar1−/−, Ifnar2−/−, Irf9−/−, and Stat1−/− BMDMs compared with WT cells          
(Figure 7-5A). On the other hand, the induction of Il18 by IFNβ was not affected in 
BMDMs lacking other IRFs, including IRF1, IRF3, IRF4, IRF5, IRF7, or IRF8 (Irf1−/−, 
Irf3−/−, Irf4fl/fl-Lysm-Cre, Irf5−/−, Irf7−/− and Irf8−/−, respectively; Figure 7-5B−C), 
suggesting that induction of Il18 is dependent on ISGF3 but not other IRFs.  
 
We have established that although both IL-18 and IL-1β belong to the IL-1 family 
and are activated by the inflammasome, IL-18 and IL-1β are differentially regulated 
(Figure 7-5D). Indeed, previous report has shown that secretion of IL-1β but not IL-18 
from murine dendritic cells in response to Listeria monocytogenes p60 protein requires 
ROS production and caspase 11 [182]. Distinctive expression patterns of IL-18 and IL-1β 
are observed in the intestine. IL-18 is expressed at high level in colon and confers 
protection against inflammation by promoting epithelial cell proliferation and tissue 
repair [183]. IL-1β, on the other hand is expressed at lower levels basally, but enhanced 
during acute inflammation [183]. Given that type I IFNs are protective against DSS-
induced colitis [184], it is possible that the type I IFNs contribute to protection by 
upregulating the expression of Il18 in the colon. Activation of the cGAS-STING pathway 
leads to the production of type I IFN [10]. Colon tissues from mice lacking STING also 
have decreased Il18 mRNA and protein expression after DSS treatment [143, 185]. 
Therefore, type I IFN signaling can be explored as a therapeutic target in IL-18–
associated diseases. We further demonstrated that Il1b gene and protein expression was 
reduced during chronic TLR stimulation in WT BMDMs, indicating that the transcription 
of Il1b or stability of Il1b mRNA may be compromised. Reduced translational activity or 
protein stability can also contribute to decreased levels of pro-IL-1β. Indeed, there is 
translational inhibition of Il1b expression in LPS-stimulated macrophages [186]. 
Moreover, pro-IL-1β is ubiquinated by E2 conjugase UBE2L3 and subsequently  
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Figure 7-4. Components of type I IFN signaling are required for induction of IL-
18. 
(A) Immunoblot analysis of pro-IL-18, pro-IL-1β, and β-actin (loading control) and real-
time qPCR analysis of genes encoding IL-18 and IL-1β in WT, Ifnar2−/−, Irf9−/−, or 
Stat1−/− BMDMs at various time points after LPS treatment. (B and C) Immunoblot 
analysis of pro-IL-18, pro-IL-1β, and β-actin (loading control) in WT, Ifnar2−/−, Irf9−/−, or 
Stat1−/− BMDMs at various time points after Pam3CSK4 (B) or poly(I:C) treatment (C). 
Data are representative of three independent experiments. 
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Figure 7-5. Type I IFNs induce IL-18 expression via ISGF3 and a model of 
differential regulation of pro-inflammatory cytokines IL-18 and IL-1β. 
(A) Immunoblot analysis of pro-IL-18 and β-actin (loading control) in WT, Ifnar2−/−, 
Irf9−/− or Stat1−/− BMDMs at various times after treated with IFNβ. (B) Real-time qPCR 
analysis of the gene encoding IL-18 in WT, Irf1−/−, Irf3−/−, Irf5−/−, Irf7−/− or Irf8−/− 
BMDMs at various times after treated with IFNβ. (C) Real-time qPCR analysis of the 
gene encoding IL-18 in WT or Irf4fl/fl-Lysm-Cre BMDMs at various times after treated 
with IFNβ. (D) Expression of IL-18 is induced and sustained by stimulations of TLR2, 
TLR4, or TLR7 ligand, while IL-1β expression declines soon after reaching its peak 
level. The TLR3 and cGAS-STING pathways also upregulate IL-18 expression but are 
modest at inducing IL-1β expression. Importantly, type I IFN signaling downstream of 
TLRs and cGAS-STING pathway is crucial in mediating IL-18 induction. Data are 
representative of three independent experiments. 
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degraded during chronic LPS stimulation [187]. This observation is in line with several 
studies showing that when macrophages are treated with TLR ligands, pro-IL-1β is 
sequestered in autophagosomes for degradation [188, 189]. Of note, we found that 
although increases in mRNA levels were similar between Il18 and Il1b in response to 
Poly(I:C) in WT BMDMs, upregulation of IL-1β protein levels was much less robust 
compared with that of IL-18 levels (Fig. 1C). This could be resulted from decreased 
translational activity of Il1b mRNA or lower stability of pro-IL-1β due to proteasome or 
autophagy-mediated degradation, revealing another layer of differential regulation 
between IL-18 and IL-1β. In addition, the modest expression of IL-1β in response to 
Poly(I:C) is supported by a previous study showing that pro-IL-1β is much less induced 
by Poly(I:C) than by LPS or gardiquimod [190]. Our study also found that 
downregulation of both Il1b mRNA and protein expression was ameliorated in cells 
lacking type I IFN signaling at later time points of LPS stimulation. An intriguing theory 
is that type I IFN signaling may be involved in the negative control of Il1b expression. 
Indeed, macrophages lacking tyrosine kinase 2, which is downstream of the type I IFN 
receptor, have increased translation of Il1b and hence high levels of pro-IL-1β in 
response to LPS [191]. Previous study has also demonstrated that type I IFN signaling 
suppresses IL-1β expression via IL-10-STAT3 signaling axis and inhibits proteolytic 
processing of IL-1β by NLRP3 inflammasome [192]. Interestingly, downregulation of 
IL-1β expression was not affected in BMDMs lacking type I IFN signaling compared 
with WT cells at later time points of Pam3CSK4 or gardiquimod stimulation (Fig. 2B, 
2C, 3B and 3C). The MyD88 pathway might induce lower production of type I IFNs and 
consequently the negative control on IL-1β is less robust as compared to the TRIF 
pathway that is activated by LPS.  
 
IL-1 family cytokines have pleiotropic functions and are involved in several 
inflammatory and autoinflammatory disease settings. Interestingly, IL-1, IL-1β and IL-
18 have specific functions in regulating disease outcomes [36]. Autoinflammatory 
models associated with overt pyrin inflammasome activation are differentially mediated 
through IL-18 [193] or IL-1β [194] production. While levels of circulating IL-1β and IL-
18 in the serum are upregulated in patients bearing activating NLRC4 or NLRP3 
mutation, IL-18 is induced to a greater extent in patients harboring mutation in NLRC4 
[195]. IL-18 is also chronically elevated in several of the autoinflammatory diseases and 
inflammasomepathies [196]. However, the cause and effect of this chronically sustained 
elevated level of IL-18 is not studied well. Our current studies demonstrate that targeting 
type I IFN signaling pathway could be a way to regulate the pathologic level of IL-18 in 
the affected patients. In summary, our study demonstrated that during chronic 
stimulation, IL-18 expression is induced and sustained. In contrast, during chronic 
stimulations IL-1β is robustly induced but not sustained. Finally, we show that type I IFN 
signaling is necessary for the induction of IL-18, but not IL-1β, which points to a critical 
and differential role for type I IFN in regulating IL-18 signaling. 
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CHAPTER 8.    DISCUSSIONS 
 
 
 Cytosolic nucleic acid sensors are pattern recognition receptors that mediate a 
range of physiological and pathological conditions. STING functions as an adaptor for 
cytosolic DNA sensing pathway induced by cGAS [10]. Our results demonstrated that 
STING is critical for protection against colon cancer by controlling overt colon 
inflammation, possibly through mediating activation of caspase-1 and casepase-1-
dependent IL-18 release. Shortly after our work was published [143], studies from other 
groups showed that expression of cGAS or STING is lost in colon carcinoma cell lines or 
gastric cancer [197, 198]. Moreover, tumor DNA has been identified to be recognized by 
cGAS-STING pathway in antigen-presenting cells leading to their activation, a process 
that requires production of type I IFNs induced by cGAS and STING [199, 200]. 
Activated antigen-presenting cells then induce potent anti-tumor CD8+ T cell responses. 
STING agonists have been further shown to provide anti-tumor responses in mouse 
models of melanoma, sarcoma, colon carcinoma, glioma, breast carcinoma, upper 
aerodigestive squamous cell carcinoma and pancreatic carcinoma [199-205]. The anti-
tumorigenic properties of STING ligands in a variety of tumor types indicate a need to 
evaluate therapeutic values of STING agonists in the clinic. Indeed, small molecules that 
activate STING pathway are currently undergoing Phase I clinical trials to treat patients 
with solid tumors or lymphomas (NCT02675439 and NCT03172936). In addition, given 
that cGAMP has been recently shown to activate inflammasome in a STING-dependent 
manner in both mouse and human myeloid cells [112, 113], it is especially important to 
monitor inflammasome responses in those cancer patients administrated with STING 
ligands.  
 
We have also demonstrated that the DNA sensor AIM2 plays a critical role in 
preventing against colon cancer induced by AOM and DSS treatment. Although AIM2 
forms the inflammasome complex with ASC and caspase-1 upon its recognition of 
cytosolic dsDNA, we showed that inflammasome responses were intact in the absence of 
AIM2 during the tumor development, as indicated by similar activation level of caspase-1 
and release of IL-18 and IL-1β in the colon and sera as WT mice. The finding showing an 
inflammasome-independent role for AIM2 in colon cancer is confirmed by a second 
study [206]. To further demonstrate this, it would be helpful to cross Aim2−/− mice with 
mice lacking other components such as Casp1−/− mice, and compared tumor outcome 
between Aim2−/− mice, Casp1−/− mice and Aim2−/−Casp1−/− mice. The inflammasome-
independent role for AIM2 in regulating tumor development would suggest an additive 
effect of tumor suppression by AIM2 and caspase-1 and that an enhanced tumor burden 
would be observed in Aim2−/−Casp1−/− mice compared with Aim2−/− mice or Casp1−/− 
mice following AOM and DSS treatment. The second study further identified that AIM2 
interacts with DNA-dependent protein kinase (DNA-PK), a protein of PI3K-related 
family to restrict activation of AKT pathway downstream of the kinase in response to the 
growth factor, insulin-like growth factor-1 (IGF-1) [206]. It would be interesting to 
identify and generate AIM2 mutants with an impaired ability to form inflammasome 
induced by cytosolic dsDNA but being able to bind to DNA-PK to regulate AKT 
pathway. We have also discovered that AIM2 negatively controls intestinal stem cell 
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activity by crossing Aim2−/− with Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen 
mouse strain and observed increased generative capacity of stem cells in 
Aim2−/−;Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen compared with 
Aim2+/+;Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen. To investigate the role of 
AIM2 in stem cell function more directly, it would be ideal to have Aim2fl/fl mice crossed 
with Prom1CreERT2-LacZ (C-L)/+; Ctnnb1lox(ex3)/+; RosaZsGreen mice to delete AIM2 in 
Prom1+ stem cell compartment and its progeny specifically.  
 
AIM2 recognizes bacterial, viral or self-derived DNA in the cytosol and forms an 
inflammasome complex leading to maturation and release of IL-1β and IL-18 and 
pyroptotic cell death [1]. AIM2 inflammasome is critical for induction of immune 
responses when host encounters a variety of infectious agents including F. novicida. 
While type I IFN signaling is required for activating AIM2 inflammasome after F. 
novicida infection [1]. We found that AIM2 inflammasome activation is intact in mice 
lacking type I IFN signaling in response to F. novicida, suggesting that type I IFN 
signaling is not required for AIM2 inflammasome activation in vivo. We showed that 
components of type I IFN signaling pathway are detrimental to the host survival during 
F. novicida infection, which is consistent with a previous study using mice lacking one 
subunit of type I IFN receptor IFNAR1 [155]. Furthermore, the deleterious type I IFN 
signaling dominates against protective AIM2 inflammasome responses by activating 
TRAIL-mediated apoptotic cell death pathway. Types of cells that are responsible for 
producing type I IFNs and TRAIL during the infection are still remained to be 
discovered. Moreover, it is intriguing to identify which cell types undergo apoptosis in a 
type I IFN signaling-dependent manner leading to the susceptibility to F. novicida 
infection. We observed induction of apoptotic cell death in F. novicida-infected liver 
tissues, where the majority of cells are hepatocytes. It is likely that hepatocytes are 
targeted by type I IFNs to cell death in the liver during the infection. Apoptosis may also 
occur in immune cells including inflammatory monocytes and tissue-resident 
macrophages such as Kupffer cells, which have important roles in antimicrobial 
activities.  
 
We further explored the role of GSDMD downstream of AIM2 inflammasome 
during F. novicida infection. Consistent with the susceptibility of mice lacking AIM2, 
ASC or caspase-1 [41, 43-45, 47, 83, 168], mice lacking GSDMD were also more 
sensitive to the infection. Interestingly, we further discovered that GSDMD is required 
for optimal caspase-1 activation in response to F. novicida, despite the fact that AIM2 
inflammasome still mediates cleavage of GSDMD to release its functional N-terminal 
fragment. GSDMD has been generally considered as the executioner of pyroptosis, our 
findings advance current understanding of the function of GSDMD and suggest a role for 
GSDMD in regulating activation of AIM2 inflammasome. In addition to AIM2 
inflammasome, GSDMD is cleaved by caspase-11 leading to activation of non-canonical 
NLRP3 inflammasome [52]. It is intriguing to hypothesize that GSDMD activates AIM2 
inflammasome or non-canonical NLRP3 inflammasome by a shared mechanism via pore 
formation on the membrane of an unknown source.  
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Our findings on distinctive mechanisms regulating the expression of 
inflammasome-associated cytokines IL-1β and IL-18 may provide explanations on 
several autoimmune diseases or infections where IL-1β and IL-18 have differential roles 
[65-67, 81, 173, 207, 208]. Given that induction of IL-18 is dependent on type I IFN 
signaling in BMDMs, effects of IL-18 should be taken into accounts in clinical therapies 
that modulate type I IFN signaling [209]. Consistent with our work, IL-18 expression is 
observed to be downregulated in Ifnar1−/− BMDMs in response to influenza virus [210]. 
Type I IFN signaling has also been shown to mediate IL-18 production by inflammatory 
monocytes during herpes simplex virus (HSV)-2 infection leading to the activation of 
natural killer (NK) cells [211], further highlighting the significance of our findings under 
pathological conditions.  
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